[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 216
1. Meulenbeld HJ, van Steenbergen LN, Janssen-Heijnen ML, Lemmens VE, Creemers GJ: Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004. Ann Oncol; 2008 Sep;19(9):1600-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004.
  • BACKGROUND: In randomised controlled trials, the median overall survival (OS) for patients with metastatic colon cancer has improved.
  • We retrospectively analysed population-based survival data of patients who presented with metastatic colon cancer at diagnosis.
  • PATIENTS AND METHODS: All patients diagnosed with primary metastatic colon cancer from 1990 to 2004 in the registration area of the Eindhoven Cancer Registry were included.
  • Date of diagnosis was divided into four periods (1990-1994, 1995-1999, 2000-2002, and 2003-2004) according to the availability of chemotherapy for metastatic colon cancer.
  • CONCLUSION: Palliative chemotherapy significantly improved OS in unselected patients with metastatic colon cancer.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467312.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL: Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol; 2008 Jun;9(6):596-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions.
  • CUP in association with a colon-cancer profile (CCP-CUP) is an example of an emerging, specific CUP subset that seems to benefit from a tailored approach.
  • CCP-CUP is identified by CK20 and CDX2-positive and CK7-negative immunohistochemistry and a clinical course consistent with that of patients known to have metastatic colon cancer.
  • Our findings suggest that patients with CCP-CUP derive substantial benefit from the use of specific treatments developed for colon cancer and larger clinical trials are warranted to more definitely test this finding.
  • [MeSH-minor] Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Neoplasm Metastasis. Patient Selection. Terminology as Topic. Treatment Outcome

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510991.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


3. Gmeiner WH, Hellmann GM, Shen P: Tissue-dependent and -independent gene expression changes in metastatic colon cancer. Oncol Rep; 2008 Jan;19(1):245-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue-dependent and -independent gene expression changes in metastatic colon cancer.
  • The goal of this study was to identify systematic alterations in key cell signaling and metabolic pathways that occur during colon cancer carcinogenesis and metastasis.
  • Gene expression levels for primary colon samples were compared to a normal colon while metastatic tissues were compared to the primary colon.
  • Primary colon samples displayed high positive z-scores (indicating a gene ontology term that occurs more frequently than expected) for genes involved in Wnt-signaling (4.11), nitrogen metabolism (7.30) and inositol phosphate metabolism (2.47).
  • Metastatic tissue from the liver and omentum, but not the lung, displayed a decreased expression of genes important for oxidative phosphorylation.
  • The metastatic tissue from all sites displayed a substantially decreased expression for genes involved in butanoate and propanoate metabolism and valine, leucine and isoleucine degradation.
  • These expression level changes complement the spectrum of mutations that characterize the progression of colorectal cancer.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097602.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA102532; United States / NCI NIH HHS / CA / P30 CA12197
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Wnt Proteins; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


Advertisement
4. Hoogerwerf WA: Biologic clocks and the gut. Curr Gastroenterol Rep; 2006 Oct;8(5):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, the development of gastrointestinal complications after administration of aspirin and after chemo- and radiotherapy for metastatic colon cancer depends on the time of administration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1993 Oct;7(10 ):1871-84 [8405996.001]
  • [Cites] Am J Gastroenterol. 2005 Jul;100(7):1491-7 [15984970.001]
  • [Cites] Chronobiol Int. 1987;4(1):111-6 [3677213.001]
  • [Cites] Neuropeptides. 2004 Aug;38(4):201-11 [15337372.001]
  • [Cites] Dis Colon Rectum. 2001 Sep;44(9):1328-32 [11584210.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Feb;17(3):353-9 [12562447.001]
  • [Cites] Cell. 1999 Jan 8;96(1):57-68 [9989497.001]
  • [Cites] Curr Pharm Des. 2001 Jul;7(10):909-31 [11472247.001]
  • [Cites] Lancet. 1997 Sep 6;350(9079):681-6 [9291901.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10 ):6488-99 [10490589.001]
  • [Cites] Chronobiol Int. 2002 Jan;19(1):129-40 [11962671.001]
  • [Cites] Genes Cells. 1998 Mar;3(3):167-76 [9619629.001]
  • [Cites] Curr Opin Genet Dev. 2003 Jun;13(3):271-7 [12787789.001]
  • [Cites] Gastroenterology. 1986 Nov;91(5):1192-7 [3758612.001]
  • [Cites] Neuron. 1998 Jun;20(6):1103-10 [9655499.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):19-22 [1733369.001]
  • [Cites] Science. 2005 May 13;308(5724):1043-5 [15845877.001]
  • [Cites] Scand J Gastroenterol. 1996 Jul;31(7):658-64 [8819214.001]
  • [Cites] Dig Dis Sci. 2002 Oct;47(10):2336-48 [12395907.001]
  • [Cites] Chronobiologia. 1989 Oct-Dec;16(4):421-39 [2697524.001]
  • [Cites] EMBO J. 1997 Nov 17;16(22):6762-71 [9362490.001]
  • [Cites] Anat Rec. 1978 Aug;191(4):479-86 [697058.001]
  • [Cites] Int J Radiat Biol. 1990 Jul;58(1):165-75 [1973434.001]
  • [Cites] Ann N Y Acad Sci. 1991;618:150-8 [1672496.001]
  • [Cites] Chronobiol Int. 1993 Dec;10(6):403-9 [8111865.001]
  • [Cites] Am J Gastroenterol. 2004 Dec;99(12):2405-16 [15571589.001]
  • [Cites] Chronobiol Int. 2005;22(6):951-61 [16393700.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Sep 8;250(1):83-7 [9735336.001]
  • [Cites] Ital J Gastroenterol. 1995 Oct-Nov;27(8):413-8 [8775466.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Apr;280(4):G629-39 [11254489.001]
  • [Cites] Gastroenterology. 1987 Sep;93(3):515-8 [3609660.001]
  • [Cites] Nature. 1970 Jun 27;226(5252):1261-2 [5422604.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):536-49 [10930389.001]
  • [Cites] Appl Ergon. 1996 Feb;27(1):9-16 [15676307.001]
  • [Cites] Dig Dis Sci. 1993 Aug;38(8):1435-40 [8344098.001]
  • [Cites] J Pineal Res. 2003 May;34(4):233-41 [12662344.001]
  • [Cites] Chronobiol Int. 2002 Jan;19(1):77-100 [11962688.001]
  • [Cites] Chronobiol Int. 2002 Jan;19(1):1-19 [11962669.001]
  • [Cites] Gastroenterology. 1994 Nov;107(5):1372-81 [7926501.001]
  • [Cites] Occup Med (Lond). 2003 Mar;53(2):103-8 [12637594.001]
  • [Cites] Am J Ind Med. 2004 Dec;46(6):586-98 [15551368.001]
  • [Cites] Curr Opin Genet Dev. 1999 Oct;9(5):588-94 [10508692.001]
  • [Cites] Bull Exp Biol Med. 2002 Dec;134(6):565-7 [12660840.001]
  • [Cites] Cancer Causes Control. 2006 May;17(4):611-21 [16596317.001]
  • [Cites] Am J Physiol. 1991 Apr;260(4 Pt 1):G610-4 [2018135.001]
  • [Cites] Nutrition. 2002 Oct;18(10):814-9 [12361772.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Nov 15;22(10):927-34 [16268966.001]
  • [Cites] Cell. 2002 Jul 26;110(2):251-60 [12150932.001]
  • [Cites] Am J Ind Med. 2002 Nov;42(5):427-36 [12382256.001]
  • (PMID = 16968601.001).
  • [ISSN] 1522-8037
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


5. Grasso G, Meli F, Patti R, Giambartino F, Florena AM, Iacopino DG: Intramedullary spinal cord tumor presenting as the initial manifestation of metastatic colon cancer: case report and review of the literature. Spinal Cord; 2007 Dec;45(12):793-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramedullary spinal cord tumor presenting as the initial manifestation of metastatic colon cancer: case report and review of the literature.
  • OBJECTIVE: Intramedullary spinal cord metastases (ISCMs) are rare type of central nervous system (CNS) involvement of systemic malignant tumors.
  • Magnetic resonance imaging of the brain did not reveal other CNS metastatic lesions.
  • Histological examination of the lesion showed the typical features of a colon carcinoma metastasis.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637763.001).
  • [ISSN] 1362-4393
  • [Journal-full-title] Spinal cord
  • [ISO-abbreviation] Spinal Cord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Chen J, Huang XF: The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther; 2009 Jul;8(14):1313-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The signal pathways in azoxymethane-induced colon cancer and preventive implications.
  • Colon cancer is the third most common cancer and third most common cause of cancer-related death in the USA according to 2008 American Cancer Society statistics.
  • The carcinogenesis of colon cancer has been associated with both genetics and environmental factors.
  • The 5 y survival rate of metastatic colon cancer is below 10%.
  • Azoxymethane (AOM) is a common model for colon cancer.
  • It can specifically induce colon cancer similar to the pathogenesis of human sporadic colon cancer.
  • Thus, it has been extensively used in the study of the molecular biology, prevention and treatment of colon cancer.
  • Mutation of K-ras activates this pathway and its downstream PI3K/Akt pathway and MAPK pathway.
  • This model has been used in the study of the genetic deficiencies of colon cancer and in the prevention and treatment of the disease.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLAZOXYMETHANOL .
  • Hazardous Substances Data Bank. METHYLAZOXYMETHANOL ACETATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502780.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Anticarcinogenic Agents; 0 / Carcinogens; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta2; 590-96-5 / methylazoxymethanol; 592-62-1 / Methylazoxymethanol Acetate; EC 1.14.13.- / Cytochrome P-450 CYP2E1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; MO0N1J0SEN / Azoxymethane
  • [Number-of-references] 58
  •  go-up   go-down


7. LaBarge MA, Bissell MJ: Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest; 2008 Jun;118(6):2021-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is CD133 a marker of metastatic colon cancer stem cells?
  • The concept of the so-called cancer stem cell (CSC) holds that only a minority of cells within a tumor have the ability to generate a new tumor.
  • In this issue of the JCI, Shmelkov et al. challenge the view that CD133 is a marker of CSCs in colon cancer (see the related article beginning on page 2111).
  • CD133 was thought previously to have a very restricted distribution within tissues; the authors have used genetic knock-in models to demonstrate that CD133 in fact is expressed on a wide range of differentiated epithelial cells in adult mouse tissues and on spontaneous primary colon tumors in mice.
  • In primary human colon tumors, all of the epithelial cells also expressed CD133, whereas metastatic colon cancers isolated from liver had distinct CD133+ and CD133- epithelial populations.
  • In light of these new findings, the popular notion that CD133 is a marker of colon CSCs may need to be revised.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5 [11121071.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12425-30 [9356465.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cell Tissue Res. 2005 Jan;319(1):15-26 [15558321.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1444-50 [17205516.001]
  • [Cites] J Pathol. 2008 Jan;214(1):3-9 [18067118.001]
  • [Cites] Pancreas. 2008 Jan;36(1):e1-6 [18192867.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):313-23 [18371365.001]
  • [CommentOn] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • (PMID = 18497883.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA064786; United States / NCI NIH HHS / CA / U54 CA126552; United States / NCI NIH HHS / CA / R01CA064786; United States / NCI NIH HHS / CA / U54CA126552
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  • [Other-IDs] NLM/ PMC2391070
  •  go-up   go-down


8. Huerta S, Baay-Guzman G, Gonzalez-Bonilla CR, Livingston EH, Huerta-Yepez S, Bonavida B: In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. Nitric Oxide; 2009 May;20(3):182-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF.
  • Primary SW480 and metastatic SW620 colon cancer cells are resistant to CDDP-induced apoptosis.
  • Examination of tumor tissues from patients with colon cancer demonstrated a significant downregulation of AIF in patients with advanced disease.
  • Altogether, these findings underscore the potential therapeutic application of NO donors and subtoxic chemotherapeutic drugs in the treatment of advanced colon cancer resistant to conventional chemotherapeutic agents.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19105980.001).
  • [ISSN] 1089-8611
  • [Journal-full-title] Nitric oxide : biology and chemistry
  • [ISO-abbreviation] Nitric Oxide
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Inducing Factor; 0 / Nitric Oxide Donors; 0 / Nitroso Compounds; 0 / RNA, Small Interfering; 146724-94-9 / 2,2'-(hydroxynitrosohydrazono)bis-ethanamine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Cienki JJ, Zaret L: An Internet misadventure: bloodroot salve toxicity. J Altern Complement Med; 2010 Oct;16(10):1125-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological examination of the lesion revealed malignant melanoma.
  • CASE REPORT 2: A 42-year-old man with a history of metastatic colon cancer developed palpable subcutaneous nodules on the anterior abdominal wall.
  • The patient's mother searched the Internet for cancer salves and purchased black and yellow bloodroot salve.
  • Web sites discuss the efficacy of bloodroot in treating skin cancer.

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20932193.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Plant Extracts
  •  go-up   go-down


10. Pasetto LM, Falci C, Rizzo E, De Salvo GL, Gasparini G, D'Andrea M, Bajetta E, Platania M, Alabiso O, Miraglia S, Oniga F, Biason R, Chetrì MC, Fedele P, Massara G, Romaniello I, Giordano M, Luchena G, Buzzi F, Ricotta R, Siena S, Monfardini S: Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units. Anticancer Res; 2008 May-Jun;28(3B):1813-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units.
  • BACKGROUND: Palliative chemotherapy significantly reduces mortality in patients with stage IV colon cancer, but is less prescribed with rising age.
  • PATIENTS AND METHODS: From January to December 2004, 78 files on the management of stage IV colorectal cancer (CRC) patients over 70 years, collected from 10 Italian Centres, were retrospectively examined.
  • CONCLUSION: In Italy, a proportion of elderly patients with metastatic chemonaive CRC are usually treated with a tolerability and overall survival similar to those for the younger population.
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease Progression. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Humans. Italy. Leucovorin / administration & dosage. Male. Medical Oncology / methods. Mitomycin / administration & dosage. Neoplasm Staging. Oncology Service, Hospital. Organoplatinum Compounds / administration & dosage. Retrospective Studies. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630465.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 50SG953SK6 / Mitomycin; 56HH86ZVCT / Uracil; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; 1-UFT protocol
  •  go-up   go-down


11. Ryan DP: Nonsurgical approaches to colorectal cancer. Oncologist; 2006 Oct;11(9):999-1002
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsurgical approaches to colorectal cancer.
  • It is time to challenge the current orthodoxy that frowns upon surgical and nonsurgical methods of tumor reduction for patients with metastatic colon cancer.
  • Although the studies conducted with radiofrequency ablation, chemoembolization, and radiation therapy in patients with metastatic colon cancer have tended to be small and may have been subject to selection bias, they have produced survival data that require careful consideration.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030641.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 039LU44I5M / Floxuridine
  • [Number-of-references] 16
  •  go-up   go-down


12. Kurkjian C, Murgo AJ, Kummar S: Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy. Clin Colorectal Cancer; 2008 Sep;7(5):321-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy.
  • The treatment of patients with metastatic colon cancer has evolved tremendously over the past 10 years, with improved overall survival (OS) rates as a result of the advent of several important agents.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Colonic Neoplasms / pathology. Colonic Neoplasms / therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794064.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 31
  •  go-up   go-down


13. Huerta S, Li HC: Bowel perforation from bevacizumab for the management of colorectal cancer. Anticancer Drugs; 2009 May;20 Spec No 2:S19-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowel perforation from bevacizumab for the management of colorectal cancer.
  • Bevacizumab (Avastin) is a recently developed monoclonal antibody, which targets the vascular endothelial growth factor receptor pathway, and is currently used in combination with cytotoxic agents as first-line or second-line therapy for patients with metastatic colon cancer.
  • In this report, we discuss a patient with bowel perforation from bevacizumab for the treatment of metastatic colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352105.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Fumagalli D, Gavin PG, Taniyama Y, Kim SI, Choi HJ, Paik S, Pogue-Geile KL: A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer; 2010 Mar 16;10:101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.
  • Our goal was to develop a high throughput, cost-effective and simple methodology for the detection of clinically relevant hot spot mutations in colon cancer.
  • METHODS: The Maldi-Tof mass spectrometry platform and OncoCarta panel from Sequenom were used to profile 239 colon cancers and 39 metastatic lymph nodes from NSABP clinical trial C-07 utilizing routinely processed FFPET (formalin-fixed paraffin-embedded tissue).
  • RESULTS: Among the 238 common hot-spot cancer mutations in 19 genes interrogated by the OncoCarta panel, mutations were detected in 7 different genes at 26 different nucleotide positions in our colon cancer samples.
  • Further evidence demonstrating the validity of the data was the fact that the mutation frequencies of the most common colon cancer mutations were similar to the COSMIC (Catalog of Somatic Mutations in Cancer) database.
  • Mutation profiling of metastatic lymph nodes and their corresponding primary tumors showed that they were 89.7% concordant.
  • CONCLUSIONS: This study describes a high throughput technology that can be used to interrogate DNAs isolated from routinely processed FFPET and identifies the specific mutations that are common to colon cancer.


15. Renouf D, Kennecke H, Gill S: Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer; 2008 Nov;7(6):386-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in chemotherapy utilization for colorectal cancer.
  • BACKGROUND: Since 1990, significant advances have occurred in the adjuvant and metastatic treatment of colorectal cancer (CRC).
  • In this study, treatment patterns of patients referred to the British Columbia Cancer Agency (BCCA) with early-stage colon cancer and metastatic CRC between 1990 and 2004 are described.
  • PATIENTS AND METHODS: This study included patients with stage II or III colon cancer or stage IV CRC at presentation referred to the BCCA during a 1-year period for 3 time cohorts: 1990, 2000, and 2004.
  • RESULTS: A total of 1421 patients were included: stage II/III, n = 915; stage IV, n = 506.
  • The proportion of patients with stage II disease treated with adjuvant CT dramatically increased (1990: 4%; 2000: 26%; 2004: 30%; P < .001).
  • [MeSH-minor] Aged. British Columbia / epidemiology. Chemotherapy, Adjuvant. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Palliative Care. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036691.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Ahmadi A, Mohagheghi M, Karimi M, Seyed Ali Golestanha, Naseri M: Anticancer effects of HESA-A in patients with metastatic colon cancer. Integr Cancer Ther; 2009 Mar;8(1):71-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer effects of HESA-A in patients with metastatic colon cancer.
  • The aim of this study was to investigate the therapeutic effects of HESA-A in patients with metastatic colon cancer.
  • METHODS: Fifty consecutive patients with end-stage colon cancer and liver metastasis at the Cancer Research Center of Tehran University of Medical Sciences were studied.
  • [MeSH-minor] Adult. Aged. Cancer Care Facilities. Female. Humans. Iran / epidemiology. Karnofsky Performance Status. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147644.001).
  • [ISSN] 1534-7354
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / HESA-A preparation; 0 / Plant Preparations
  •  go-up   go-down


17. Manuelli M, De Luca L, Iaria G, Tatangelo P, Sforza D, Perrone L, Bellini MI, Angelico R, Anselmo A, Tisone G: Conversion to rapamycin immunosuppression for malignancy after kidney transplantation. Transplant Proc; 2010 May;42(4):1314-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rapamycin has been shown to limit the proliferation of a number of malignant cell lines in vivo and in vitro.
  • METHODS: Fifteen patients developed the following malignancies at a mean of 90.3 months (range = 10-252) after kidney transplantation: metastatic gastric cancer (n = 1), metastatic colon cancer (n = 1), bilateral nephrourothelioma (n = 1), skin cancer (n = 2), Kaposi's sarcoma (n = 2), posttransplant lymphoproliferative disorder (PTLD; n = 4), renal cell carcinoma T1 (n = 1), MALT lymphoma (n = 1), intramucous colon carcinoma (n = 1), liposarcoma of the spermatic cord (n = 1).
  • RESULTS: Both patients with metastatic cancer underwent chemotherapy but succumbed after 6 and 13 months.
  • At a mean follow-up of 32.7 months (range = 7-56), the remaining 11 patients are cancer-free.
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor. Colonic Neoplasms / immunology. Colonic Neoplasms / pathology. Genital Neoplasms, Male / immunology. Genital Neoplasms, Male / pathology. Humans. Immunosuppression / methods. Immunosuppressive Agents / therapeutic use. Liposarcoma / immunology. Liposarcoma / pathology. Male. Neoplasm Metastasis. Skin Neoplasms / immunology. Skin Neoplasms / pathology. Stomach Neoplasms / immunology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Inc.
  • (PMID = 20534289.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


18. Iwazawa J, Ohue S, Hashimoto N, Yasumasa K, Abe H, Mitani T: Bevacizumab-induced hypovascular hepatocellular carcinoma treated by transarterial chemoembolization in a patient with metastatic colon cancer. J Vasc Interv Radiol; 2010 Mar;21(3):412-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab-induced hypovascular hepatocellular carcinoma treated by transarterial chemoembolization in a patient with metastatic colon cancer.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20116287.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


19. Hiraki M, Yakushiji H, Hashiguchi K, Harada S: [Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report]. Gan To Kagaku Ryoho; 2005 Jul;32(7):1055-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report].
  • Combined chemotherapy consisting of oral TS-1 and low-dose CPT-11 by hepatic arterial infusion is suggested to be a new effective treatment for multiple liver metastases from colorectal cancer.
  • A 53-year-old man was diagnosed with multiple hepatic metastases from advanced colon cancer (Stage IV).
  • The patient underwent partial resection of the colon and catheter insertion into hepatic artery for arterial infusion in November 2003.
  • In spite of the reduction of metastatic liver tumors after 2 cycles of the chemotherapy, a metastatic pleural tumor appeared.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044973.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


20. Papila B, Yildiz O, Tural D, Delil S, Hasiloglu ZI, Ayan F, Papila C: Wernicke's Encephalopathy in Colon Cancer. Case Rep Oncol; 2010;3(3):362-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wernicke's Encephalopathy in Colon Cancer.
  • In this case report, we present a 56-year-old female patient with metastatic colon cancer complicated with enterocutaneous fistula.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1976;33(5-6):250-2 [1026857.001]
  • [Cites] Nutrition. 2009 Feb;25(2):142-6 [18929463.001]
  • [Cites] Chemotherapy. 1979;25(2):70-6 [446187.001]
  • [Cites] Int J Vitam Nutr Res. 1974;44(1):53-8 [4838352.001]
  • [Cites] Ann N Y Acad Sci. 1982;378:316-26 [7044226.001]
  • (PMID = 21537379.001).
  • [ISSN] 1662-6575
  • [Journal-full-title] Case reports in oncology
  • [ISO-abbreviation] Case Rep Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3085069
  • [Keywords] NOTNLM ; 5-fluorouracil / Thiamine / Wernicke's encephalopathy
  •  go-up   go-down


21. Burz C, Berindan-Neagoe IB, Balacescu O, Tanaselia C, Ursu M, Gog A, Vlase L, Chintoanu M, Balacescu L, Leucuta SE, Irimie A, Cristea V: Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. J Gastrointestin Liver Dis; 2009 Mar;18(1):39-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
  • AIM: to evaluate the therapeutic efficacy of oxaliplatin and to analyze the pharmacokinetics of both ultrafiltrable (free) and protein-bound platinum in patients with metastatic colon cancer.
  • METHOD: 60 patients with stage IV colon carcinoma received 4-6 (mean 4.5) cycles of oxaliplatin based combination chemotherapy.
  • CONCLUSION: Oxaliplatin is active and well tolerated in patients with advanced colon cancer.
  • [MeSH-minor] Adult. Aged. Area Under Curve. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / blood. Fluorouracil / pharmacokinetics. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leucovorin / blood. Leucovorin / pharmacokinetics. Male. Mass Spectrometry. Metabolic Clearance Rate. Middle Aged. Neoplasm Staging. Protein Binding. Time Factors. Treatment Outcome

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19337632.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


22. Agarwal V, Sgouros J, Smithson J, Lodge JP, Razack A, Campbell A, Maraveyas A: Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report. J Med Case Rep; 2008;2:227
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report.
  • INTRODUCTION: We present the case of a patient with colon cancer who, while receiving bevacizumab, developed sinusoidal obstruction syndrome (veno-occlusive disease) (SOSVOD).
  • CASE PRESENTATION: A 77-year-old man was being treated with oxaliplatin and a modified de Gramont regimen of 5-fluorouracil for metastatic colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2004 Mar;15(3):460-6 [14998849.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2065-72 [16648507.001]
  • [Cites] J Cell Mol Med. 2005 Oct-Dec;9(4):777-94 [16364190.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9073-8 [16361615.001]
  • (PMID = 18620573.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2481264
  •  go-up   go-down


23. Kishimoto H, Urata Y, Tanaka N, Fujiwara T, Hoffman RM: Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Mol Cancer Ther; 2009 Nov;8(11):3001-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.
  • We assessed the antitumor efficacy of OBP-301 and the ability of OBP-401 to deliver GFP in hepatocellular carcinoma (HCC) and metastatic colon cancer nude mouse models.
  • We showed that i.v. administration of OBP-301 significantly inhibited colon cancer liver metastases and orthotopically implanted HCC.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 2006 Feb 1;312(3):256-65 [16356494.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3848-56 [16799626.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6259-65 [15342413.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):285-92 [14734481.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii13-6 [12810452.001]
  • [Cites] Cancer Gene Ther. 2008 May;15(5):315-22 [18274558.001]
  • [Cites] Am J Surg. 1999 Apr;177(4):303-6 [10326848.001]
  • [Cites] Hepatogastroenterology. 2007 Dec;54(80):2232-9 [18265640.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):385-90 [18201270.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Apr;5(2):337-52 [9019355.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3130-40 [15735729.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1213-9 [17013385.001]
  • [Cites] Biotechniques. 2005 Aug;39(2):170, 172 [16116787.001]
  • [Cites] J Hepatol. 2000;32(1 Suppl):225-37 [10728807.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):551-7 [9973199.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):432-40 [16477640.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2628-33 [18338751.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):29-34 [12832962.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1528-38 [18754863.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8490-9 [16230676.001]
  • [Cites] Cancer. 1989 Nov 1;64(9):1848-52 [2477137.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2 [8857855.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):796-806 [16195751.001]
  • (PMID = 19887549.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R43 CA132242; United States / NCI NIH HHS / CA / CA132242
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


24. Vitale S, Cambien B, Karimdjee BF, Barthel R, Staccini P, Luci C, Breittmayer V, Anjuère F, Schmid-Alliana A, Schmid-Antomarchi H: Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut; 2007 Mar;56(3):365-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer.
  • Here, we investigate the antitumour effect of fractalkine, in its three molecular forms, in two orthotopic models of metastatic colon cancer (liver and lung) and in the standard subcutaneous model.
  • METHODS: We have developed models of skin tumours, liver and pulmonary metastasis and compared the extent of tumour development between C26 colon cancer cells expressing either the native, the soluble, the membrane-bound fractalkine or none.
  • CONCLUSIONS: Fractalkine expression by C26 tumour cells drastically reduces their metastatic potential in the two physiological target organs.
  • [MeSH-minor] Animals. Chemokine CX3CL1. Disease Models, Animal. Female. Genetic Therapy / methods. Genetic Vectors. Immunophenotyping. Liver Neoplasms / immunology. Liver Neoplasms / pathology. Liver Neoplasms / prevention & control. Liver Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Lymphocytes, Tumor-Infiltrating / immunology. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Skin Neoplasms / immunology. Skin Neoplasms / prevention & control. Skin Neoplasms / secondary. Transfection

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 1999 Aug;29(8):2551-9 [10458770.001]
  • [Cites] J Exp Med. 1998 Dec 21;188(12):2357-68 [9858522.001]
  • [Cites] Int J Oncol. 2005 Jan;26(1):41-7 [15586223.001]
  • [Cites] Biochem J. 2005 Feb 15;386(Pt 1):15-27 [15554875.001]
  • [Cites] Eur J Immunol. 2005 May;35(5):1371-80 [15789339.001]
  • [Cites] Nat Immunol. 2000 Oct;1(4):298-304 [11017100.001]
  • [Cites] J Leukoc Biol. 2001 Apr;69(4):522-30 [11310837.001]
  • [Cites] J Biol Chem. 2001 Oct 12;276(41):37993-8001 [11495925.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):44622-6 [11571300.001]
  • [Cites] Inflamm Res. 2001 Nov;50(11):529-33 [11766992.001]
  • [Cites] Gastrointest Endosc. 2002 May;55(6):755-9 [11979269.001]
  • [Cites] Nature. 2002 Oct 17;419(6908):734-8 [12384702.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):212-20 [12455035.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1186-95 [12714508.001]
  • [Cites] Immunol Lett. 2003 Oct 9;89(1):1-7 [12946858.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7468-74 [14612547.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1540-7 [14734732.001]
  • [Cites] Nat Rev Immunol. 2004 Mar;4(3):231-7 [15039760.001]
  • [Cites] Cancer Res. 1978 Jun;38(6):1739-44 [647684.001]
  • [Cites] Nature. 1997 Feb 13;385(6617):640-4 [9024663.001]
  • [Cites] Cell. 1997 Nov 14;91(4):521-30 [9390561.001]
  • [Cites] Nature. 1998 Jun 4;393(6684):413-4 [9623994.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10896-901 [9724801.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1565-72 [9766501.001]
  • [Cites] J Exp Med. 1998 Oct 19;188(8):1413-9 [9782118.001]
  • [CommentIn] Gut. 2007 Mar;56(3):314-6 [17339240.001]
  • (PMID = 16870716.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokine CX3CL1; 0 / Chemokines, CX3C; 0 / Cx3cl1 protein, mouse; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC1856814
  •  go-up   go-down


25. Toema BM: A patient with metastatic colon cancer to the liver presenting with cardiac arrest status post receiving combination irinotecan-panitumumab: a case report. J Exp Ther Oncol; 2010;8(4):321-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with metastatic colon cancer to the liver presenting with cardiac arrest status post receiving combination irinotecan-panitumumab: a case report.
  • A Fifty three years old male with metastatic colon cancer to the liver started Panitumumab-Irinotecan palliative combination chemotherapy.
  • The aim of reporting this adverse event is to emphasize the recommendations of the National Comprehensive Cancer Network of discontinuing the use of Panitumumab-chemotherapy combination in metastatic colon cancer patients.

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21222364.001).
  • [ISSN] 1359-4117
  • [Journal-full-title] Journal of experimental therapeutics & oncology
  • [ISO-abbreviation] J. Exp. Ther. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / panitumumab; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


26. Kim HW, Won KS, Kwon KY, Choi BW, Zeon SK: Metastatic colon cancer to the lung with no detectable primary tumor, mimicking advanced primary lung cancer on F-18 FDG PET/CT imaging. Clin Nucl Med; 2010 Mar;35(3):184-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic colon cancer to the lung with no detectable primary tumor, mimicking advanced primary lung cancer on F-18 FDG PET/CT imaging.
  • CT-guided biopsy of the right lung mass revealed metastatic adenocarcinoma from the colon, but a colon cancer lesion was not detected by dynamic abdominal CT and colonoscopy.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173453.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


27. Shoji H, Kuroki M, Hiramoto K, Matsumura Y, Miura A, Kikuchi Y, Hirakawa H: [A case of metastatic colorectal cancer suffering from hyperammonemic encephalopathy induced by 5-FU, continuously treated with FOLFOX therapy]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1583-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic colorectal cancer suffering from hyperammonemic encephalopathy induced by 5-FU, continuously treated with FOLFOX therapy].
  • We report a rare case of metastatic colorectal cancer who suffered from hyperammonemic encephalopathy induced by 5- FU and was continuously treated with FOLFOX therapy.
  • A 50-year-old man with ileus was diagnosed with ascending colon cancer Stage IV, and a right hemicolectomy was performed.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716892.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amino Acids, Branched-Chain; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


28. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther; 2010 Apr;18(4):843-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In an attempt to treat cancer patients with ERBB2 overexpressing tumors, we developed a chimeric antigen receptor (CAR) based on the widely used humanized monoclonal antibody (mAb) Trastuzumab (Herceptin).
  • An optimized CAR vector containing CD28, 4-1BB, and CD3zeta signaling moieties was assembled in a gamma-retroviral vector and used to transduce autologous peripheral blood lymphocytes (PBLs) from a patient with colon cancer metastatic to the lungs and liver, refractory to multiple standard treatments.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3617-27 [12516549.001]
  • [Cites] Mol Ther. 2010 Feb;18(2):413-20 [19773745.001]
  • [Cites] Clin J Oncol Nurs. 2004 Aug;8(4):415-6 [15354929.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5650-5 [15355889.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):250-61 [2644399.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Transplantation. 1990 Apr;49(4):697-702 [2109379.001]
  • [Cites] Oncogene. 1990 Jul;5(7):953-62 [1973830.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):8002-9 [1979253.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9 [1350088.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4 [8421711.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4586-93 [7553634.001]
  • [Cites] Toxicology. 1995 Dec 20;105(1):23-9 [8638282.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] Immunity. 2005 Apr;22(4):403-14 [15845446.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3676-85 [15738535.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7536-45 [16157940.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):5799-808 [16237072.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] Intensive Care Med. 2006 Feb;32(2):260-6 [16435103.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):e20-2 [16648493.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Jul;291(1):G16-25 [16769812.001]
  • [Cites] J Mol Med (Berl). 2006 Aug;84(8):671-81 [16607561.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):1018-28 [16908486.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15 [17062687.001]
  • [Cites] J Immunother. 2006 Nov-Dec;29(6):616-27 [17063124.001]
  • [Cites] Mol Ther. 2007 Apr;15(4):825-33 [17299405.001]
  • [Cites] N Engl J Med. 2007 Jul 5;357(1):39-51 [17611206.001]
  • [Cites] J Immunol. 2007 Sep 1;179(5):3325-31 [17709549.001]
  • [Cites] J Transl Med. 2007;5:42 [17822557.001]
  • [Cites] Int J Immunogenet. 2007 Dec;34(6):413-8 [18001296.001]
  • [Cites] Cancer Immunol Immunother. 2008 Feb;57(2):271-80 [17646988.001]
  • [Cites] Cell. 2007 Nov 30;131(5):1018 [18045542.001]
  • [Cites] Injury. 2007 Dec;38(12):1336-45 [18048040.001]
  • [Cites] Handb Exp Pharmacol. 2008;(181):329-42 [18071952.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11991-9 [18089830.001]
  • [Cites] J Transl Med. 2008;6:25 [18485193.001]
  • [Cites] Am J Emerg Med. 2008 Jul;26(6):711-5 [18606328.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2261-71 [18509084.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5233-9 [18809613.001]
  • [Cites] Nat Med. 2008 Nov;14(11):1264-70 [18978797.001]
  • [Cites] Clin Lab Med. 2008 Sep;28(3):423-40, vi [19028261.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5 [19211796.001]
  • [Cites] Immunol Rev. 2009 May;229(1):192-215 [19426223.001]
  • [Cites] Blood. 2009 Jul 16;114(3):535-46 [19451549.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5027-37 [15297404.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Cancer Invest. 2001;19(5):554-68 [11458821.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 1:S3-8 [11521719.001]
  • [Cites] Curr Opin Immunol. 2001 Oct;13(5):572-6 [11544006.001]
  • [Cites] Genes Immun. 2001 Oct;2(6):297-303 [11607784.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2624-32 [12039923.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):35-45 [12509765.001]
  • [Cites] Mol Ther. 2009 Aug;17(8):1453-64 [19384291.001]
  • [Cites] Breast Cancer Res Treat. 2009 Sep;117(1):83-9 [19051009.001]
  • [Cites] J Immunol. 2009 Nov 1;183(9):5563-74 [19843940.001]
  • [Cites] Hum Gene Ther. 2008 Nov;19(11):1219-32 [19848582.001]
  • [Cites] Curr Gene Ther. 2009 Oct;9(5):396-408 [19860654.001]
  • [Cites] Curr Opin Biotechnol. 2009 Dec;20(6):673-7 [19892543.001]
  • [CommentIn] Mol Ther. 2010 Apr;18(4):661-2 [20357776.001]
  • (PMID = 20179677.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD3; 0 / Cytokines; 0 / Receptors, Antigen, T-Cell; 0 / Recombinant Fusion Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ PMC2862534
  •  go-up   go-down


29. Holen KD: Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer. Cancer Invest; 2006 Feb;24(1):98-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer.
  • There have been many recent advances in the field of systemic chemotherapy for metastatic colorectal cancer.
  • Although the decision regarding colorectal cancer chemotherapy is now more complicated, our patients have certainly benefited from better response rates and most importantly, longer survival times.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466998.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; 9007-49-2 / DNA; EC 2.1.1.45 / Thymidylate Synthase; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 5.99.1.2 / DNA Topoisomerases, Type I; U3P01618RT / Fluorouracil
  • [Number-of-references] 59
  •  go-up   go-down


30. Castillo-Fernández O, Santibáñez M, Bauza A, Calderillo G, Castro C, Herrera R, Serrano A, Arrieta O, Herrera LA: Methylenetetrahydrofolate reductase polymorphism (677 C&gt;T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid. Arch Med Res; 2010 Aug;41(6):430-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase polymorphism (677 C>T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid.
  • BACKGROUND AND AIMS: Fluoropyrimidine-based chemotherapy is the most common treatment for unresectable metastatic colorectal cancer (m-CRC).
  • Pharmacogenomics allows the tailoring of cancer therapy to the patient.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 IMSS. Published by Elsevier Inc. All rights reserved.
  • (PMID = 21044746.001).
  • [ISSN] 1873-5487
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Kurtz JE, Claudel L, Collard O, Limacher JM, Bergerat JP, Dufour P: Liver abscess due to clostridium septicum. A case report and review of the literature. Hepatogastroenterology; 2005 Sep-Oct;52(65):1557-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The onset of liver abscess due to Clostridium septicum -an anaerobic gram-positive bacillus- is a rare condition, generally arising in cancer patients.
  • We report a case of a 50-year-old patient with metastatic colon cancer who was referred with multiple Clostridium septicum liver abscesses.
  • Clostridium septicum liver abscess is a life-threatening condition that occurs in fragile patients, mostly with metastatic cancers.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16201118.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


32. Vaidyanathan G, Fakih MG: A case of curative-intent hepatectomy for colon cancer metastatic to the scapula and liver. Anticancer Res; 2010 Feb;30(2):677-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of curative-intent hepatectomy for colon cancer metastatic to the scapula and liver.
  • Colon cancer is the second leading cause of cancer death in the United States.
  • Patients with colon cancer metastatic to liver and bone are deemed non-curable and have a poor prognosis.
  • We present a case of recurrent colon cancer with synchronous hepatic and bony metastases treated with radiation, chemotherapy, and curative-intent hepatectomy.


33. Tscharner GG, Bühler S, Borner M, Hunziker T: Grover's disease induced by cetuximab. Dermatology; 2006;213(1):37-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 71-year-old man exhibited an acute acneiform rash affecting the face and the upper trunk about 2 weeks after starting cetuximab, an epidermal growth factor (EGF) receptor antagonist treatment for metastatic colon cancer.

  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778425.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


34. Xu F, Ye YJ, Liu W, Kong M, He Y, Wang S: Dendritic cell/tumor hybrids enhances therapeutic efficacy against colorectal cancer liver metastasis in SCID mice. Scand J Gastroenterol; 2010 Jun;45(6):707-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell/tumor hybrids enhances therapeutic efficacy against colorectal cancer liver metastasis in SCID mice.
  • OBJECTIVE: Colorectal cancer (CRC) is one of the most common malignancies in the western world.
  • Although surgical resection is the first choice worldwide, at this point an effective approach for the treatment of patients with liver metastasis and cancer recurrence postoperation has not yet been found.
  • The aim of this study is to investigate the role of the allogeneic dendritomas from fusion of DCs and metastatic colon cancer cells in the activation of anti-tumor immunity against colorectal cancer liver metastases.
  • MATERIAL AND METHODS: Hybrids were generated by fused allogeneic human peripheral blood dendritic cells with metastatic colon cancer SW620 cells using 50% polyethylene glycol (PEG).
  • CONCLUSIONS: Vaccination with hybrids can induces strong cellular responses and significant protection from challenge in SCID mouse metastatic CRC model.


35. Garufi C, Ettorre GM, Vanni B, Torsello A, Terzoli E: Neoadjuvant chemotherapy for metastatic colon cancer: too much caution and still too much to be assessed. J Clin Oncol; 2006 May 10;24(14):2217-8; author reply 2218-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy for metastatic colon cancer: too much caution and still too much to be assessed.
  • [MeSH-minor] Humans. Neoadjuvant Therapy. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2005 Dec 20;23(36):9073-8 [16361615.001]
  • (PMID = 16682743.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


36. Mis L, Fernando NH, Hurwitz HI, Morse MA: Successful desensitization to oxaliplatin. Ann Pharmacother; 2005 May;39(5):966-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE SUMMARY: A 53-year-old white woman with metastatic colon cancer was receiving oxaliplatin, bevacizumab, and capecitabine every 2 weeks, with a partial response to therapy.
  • CONCLUSIONS: Hypersensitivity reactions to platinum compounds may result in discontinuation of active therapies in patients with metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15784807.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


37. Fernandes H, D'Souza CR, Swethadri GK, Naik CN: Ameboma of the colon with amebic liver abscess mimicking metastatic colon cancer. Indian J Pathol Microbiol; 2009 Apr-Jun;52(2):228-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ameboma of the colon with amebic liver abscess mimicking metastatic colon cancer.
  • Amebic colitis is common in developing countries, with its variable and non-specific symptoms.
  • Amebomas occur rarely, resulting from the formation of annular granulation tissue, usually in the cecum and in the ascending colon.
  • The endoscopy performed showed a growth in the ascending colon.
  • The patient was referred to this hospital for surgical treatment with a provisional diagnosis of carcinoma of the colon.
  • Histological examination of the right hemicolectomy specimen revealed cecal and ascending colon amebomas.
  • Colonic ameboma accompanied by amebic liver abscess may be misdiagnosed as metastatic colon cancer.

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332922.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


38. McCormick CC, Giuntoli RL 2nd, Gardner GJ, Schulick RD, Judson K, Ronnett BM, Vang R, Bristow RE: The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol; 2007 Jun;105(3):791-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytoreductive surgery for colon cancer metastatic to the ovary.
  • OBJECTIVE: We sought to further elucidate the survival impact of cytoreductive surgery among patients with colon cancer metastatic to the ovary.
  • METHODS: All women diagnosed with primary colon cancer metastatic to the ovary at a single institution from 1980 to 2005 were retrospectively identified.
  • RESULTS: A total of 39 patients with 40 cases of colon cancer metastatic to the ovary were identified.
  • Patients with metastatic disease confined to the ovaries (n=11) had a median overall survival (OS) time of 61 months (range 15-120) compared to 17 months (range 0.5-73) for those with more extensive metastases (n=24) (p=0.0428).
  • CONCLUSIONS: The observation that optimal cytoreduction was associated with prolonged PFS and OS in both patients with localized ovarian and widespread metastases of colon cancer suggests a role for surgical management of metastatic colon cancer in women.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17408727.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Berber E, Siperstein AE: Perioperative outcome after laparoscopic radiofrequency ablation of liver tumors: an analysis of 521 cases. Surg Endosc; 2007 Apr;21(4):613-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Radiofrequency thermal ablation (RFA) is gaining increased acceptance for the treatment of unresectable primary and metastatic liver tumors.
  • The pathology was metastatic colon cancer for 244 patients (47%), hepatocellular cancer for 109 patients (21%), metastatic neuroendocrine cancer for 74 patients (14%), and other noncolorectal, nonneuroendocrine liver metastasis for 94 patients (18%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Biopsy, Needle. Cohort Studies. Female. Follow-Up Studies. Hepatectomy / methods. Humans. Immunohistochemistry. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Perioperative Care. Probability. Prospective Studies. Regression Analysis. Risk Assessment. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2000 Apr;14(4):400-5 [10790563.001]
  • [Cites] World J Surg. 2002 Aug;26(8):985-90 [12016479.001]
  • [Cites] Surg Endosc. 2005 May;19(5):710-4 [15759186.001]
  • [Cites] Surg Endosc. 2005 Dec;19(12):1613-7 [16247574.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):106-13 [10761788.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):1-8 [10400029.001]
  • [Cites] J Urol. 1961 Sep;86:321-9 [13763692.001]
  • [Cites] J Vasc Interv Radiol. 1992 May;3(2):291-7 [1627876.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):864-9 [11485520.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1358-64 [15684312.001]
  • (PMID = 17287917.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Thomas A, Lenox R: Pulmonary lymphangitic carcinomatosis as a primary manifestation of colon cancer in a young adult. CMAJ; 2008 Aug 12;179(4):338-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary lymphangitic carcinomatosis as a primary manifestation of colon cancer in a young adult.
  • Pulmonary lymphangitic carcinomatosis is a metastatic lung disease characterized by diffuse spread of the tumour to the pulmonary lymphatic system.
  • However, results of a transbronchial biopsy led to the diagnosis of pulmonary lymphangitic carcinomatosis from metastatic colon cancer.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Chest. 1983 Dec;84(6):787-8 [6641323.001]
  • [Cites] Intern Med. 2007;46(8):491-4 [17443041.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1481-7 [9593786.001]
  • [Cites] J R Coll Surg Edinb. 1996 Feb;41(1):7-13 [8930034.001]
  • (PMID = 18695182.001).
  • [ISSN] 1488-2329
  • [Journal-full-title] CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • [ISO-abbreviation] CMAJ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2492966
  •  go-up   go-down


41. Chennat J, Waxman I: Initial performance profile of a new 6F self-expanding metal stent for palliation of malignant hilar biliary obstruction. Gastrointest Endosc; 2010 Sep;72(3):632-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial performance profile of a new 6F self-expanding metal stent for palliation of malignant hilar biliary obstruction.
  • BACKGROUND: A 6F endoscopic biliary self-expanding metal stent (SEMS) has been newly introduced for intended simultaneous side-by-side bilateral deployment in hilar malignant obstruction.
  • PATIENTS: Sixteen consecutive malignant hilar biliary obstruction patients.
  • INTERVENTIONS: Endoscopic palliative treatment of malignant biliary obstruction with the Zilver 635 SEMS from December 2008 to January 2010.
  • RESULTS: A total of 49 Zilver SEMSs were placed in 16 patients (mean age 61 years, 6 men) for Bismuth type II (n = 4), III (n = 5), and IV (n = 7) lesions.
  • Twelve had cholangiocarcinoma, 2 had metastatic colon cancer, 1 had lung cancer, and 1 had pancreatic cancer.
  • CONCLUSIONS: Malignant hilar biliary obstruction endoscopic palliation with the Zilver 635 SEMS offers acceptable initial feasibility, safety, and efficacy profiles.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Mosby, Inc.
  • (PMID = 20579991.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alloys; 52013-44-2 / nitinol
  •  go-up   go-down


42. Damjanov N: Commentary: Colonoscopic findings and tumor site do not predict bowel obstruction during medical treatment of stage IV colon cancer. Oncologist; 2009 Jun;14(6):578-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Commentary: Colonoscopic findings and tumor site do not predict bowel obstruction during medical treatment of stage IV colon cancer.
  • [MeSH-minor] Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Oncologist. 2009 Jun;14(6):580-5 [19465681.001]
  • (PMID = 19482957.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Hsu TC: Unusual elevation of CEA in a patient with history of colon cancer. Jpn J Clin Oncol; 2006 Dec;36(12):811-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual elevation of CEA in a patient with history of colon cancer.
  • A 35-year-old female received right hemicolectomy for a poorly differentiated adenocarcinoma of the ascending colon with lymph node metastasis (1/28) in February 1997.
  • She received bilateral salpingo-ophorecctomy for metastatic cancer in August 1999.
  • CEA was found to be 240.3 ng/microl in December 1999 and then elevated to 1521.3 ng/microl in June 2001, which was 10 months after resection of metastatic ovarian cancer.
  • No metastatic lesions could be detected, however, with image studies.
  • The current case suggested that: (i) elevation of CEA is not necessarily well correlated with presence of metastatic colon cancer;.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060406.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


44. Katsumata K, Sumi T, Wada T, Mori Y, Hisada M, Kawakita H, Enomoto M, Suzuki S, Matsuda D, Tsuchida A, Aoki T: Oxaliplatin for metastatic colon cancer in a patient with renal failure. Clin Med Oncol; 2008;2:97-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin for metastatic colon cancer in a patient with renal failure.
  • OBJECTIVE: Oxaliplatin, a key part of the standard regimen for colorectal cancer in Western countries, has become available in Japan.
  • In a hemodialysis patient with cecal cancer, we investigated the efficacy, safety, pharmacokinetics, and dialysability of oxaliplatin.
  • METHODS: A 65-year-old man who had cecal cancer was treated with oxaliplatin (40 mg/m(2)) and l-leucovorin(l-LV) (200 mg/m(2)), which were administered simultaneously over 120 min via the side and main arms of a Y-tube, respectively.
  • RESULTS: The patient received 3 courses of oxaliplatin before he died of cancer.
  • Such data will assist in treating the rapidly increasing number of hemodialysis patients with colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2000;45(2):157-64 [10663631.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jul;30(7):318-21 [11007166.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Nov;27(13):2135-8 [11103248.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5970-6 [8261411.001]
  • [Cites] Biochem Pharmacol. 1996 Dec 24;52(12):1855-65 [8951344.001]
  • [Cites] J Pharm Biomed Anal. 2000 Dec;24(1):1-10 [11108533.001]
  • [Cites] Gan To Kagaku Ryoho. 1987 Sep;14(9):2771-4 [3631976.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2664-72 [12860942.001]
  • (PMID = 21892270.001).
  • [ISSN] 1177-9314
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3161642
  • [Keywords] NOTNLM ; colorectal cancer / hemodialysis / oxaliplatin / renal failure
  •  go-up   go-down


45. Press OA, Zhang W, Gordon MA, Yang D, Lurje G, Iqbal S, El-Khoueiry A, Lenz HJ: Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res; 2008 Apr 15;68(8):3037-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer.
  • Sex steroid hormone receptors are expressed in the colon and interact with epidermal growth factor receptor (EGFR), a gene widely expressed in colonic tissue.
  • Increased EGFR expression is linked with poor prognosis in colon cancer.
  • These germ-line polymorphisms of EGFR were analyzed in genomic DNA from 318 metastatic colon cancer patients, 177 males and 141 females, collected from 1992 to 2003.
  • This study supports the role of functional EGFR polymorphisms as independent prognostic markers in metastatic colon cancer.
  • [MeSH-minor] Colorectal Neoplasms / genetics. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Humans. Male. Neoplasm Metastasis. Recurrence. Retrospective Studies. Sex Characteristics. Survival Analysis

  • Genetic Alliance. consumer health - Metastatic cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413774.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 K24CA827540
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


46. Iacovazzi PA, Notarnicola M, Caruso MG, Guerra V, Frisullo S, Altomare DF, Correale M: Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients. Immunopharmacol Immunotoxicol; 2010 Mar;32(1):160-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients.
  • In our study, we have evaluated levels of both glycoproteins in sera of non metastatic colon cancer patients.
  • Interestingly, galectin-3 ranged higher in cancer patients than in controls (p<0.0001), particularly in more differentiated tumors (p<0.04).
  • Moreover, 90K mean values ranged higher in right-side than in left-side colon cancer.
  • In conclusion, serum galectin3 might represent a useful biomarker to evaluate colon cancer transformation and, together with its ligand 90K, could contribute to the characterization of colon cancer.
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, Neoplasm. Biomarkers, Tumor. Female. Galectin 3 / blood. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 3.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19686089.001).
  • [ISSN] 1532-2513
  • [Journal-full-title] Immunopharmacology and immunotoxicology
  • [ISO-abbreviation] Immunopharmacol Immunotoxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Galectin 3; 0 / Glycoproteins; 0 / LGALS3BP protein, human
  •  go-up   go-down


47. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, Vázquez J, Lasalvia-Galante E, Golomar W, Larrañga J: Advanced colon cancer: antiprogressive immunotherapy using an autologous hemoderivative. Med Oncol; 2006;23(1):91-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced colon cancer: antiprogressive immunotherapy using an autologous hemoderivative.
  • INTRODUCTION: Advanced colon cancer patients, acquired-chemotherapy resistant and in progression, are therapeutically terminal.
  • PATIENTS AND METHODS: Metastatic colon cancer patients chemotherapy-resistant, high CEA plasma levels, in progression, were 2-group randomized.
  • CONCLUSION: The autologous hemoderivative tested is antigenically polyvalent and promotes a polytargeted immune response associated with a tumor antiprogressive effect, consequently, acting as an autologous hemoderivative cancer vaccine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nat Toxins. 1998 Feb;7(1):37-44 [9689601.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2736-44 [11675346.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):631-5 [11237383.001]
  • [Cites] Cancer Res. 1982 Nov;42(11):4862-6 [7127320.001]
  • [Cites] Lancet. 1988 Jun 4;1(8597):1284-5 [2897547.001]
  • [Cites] Biull Eksp Biol Med. 1982 Apr;93(4):66-8 [6805529.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3558-85 [11032599.001]
  • [Cites] Cancer Biol Ther. 2003 Mar-Apr;2(2):155-60 [12750554.001]
  • [Cites] J Immunother. 1999 Mar;22(2):166-74 [10093041.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2756-61 [12193750.001]
  • [Cites] Folia Clin Int (Barc). 1965 Jun;15(6):303-8 [5845419.001]
  • (PMID = 16645234.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


48. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol; 2009 Dec 10;27(35):5924-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
  • PURPOSE: The occurrence of KRAS mutation is predictive of nonresponse and shorter survival in patients treated by anti-epidermal growth factor receptor (anti-EGFR) antibody for metastatic colorectal cancer (mCRC), leading the European Medicine Agency to limit its use to patients with wild-type KRAS tumors.


49. Andreis F, Rizzi A, Mosconi P, Braun C, Rota L, Meriggi F, Mazzocchi M, Zaniboni A: Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes; 2010;8:40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study.
  • This monocentric cross sectional study is carried out to assess quality of life in colon cancer patients experienced skin side effects due to anti epidermal growth factor receptor inhibitors therapy.
  • RESULTS: Forty-five consecutive patients, mainly with metastatic colon cancer (29 female, 16 male), with an average age of 59.31 years (ranging from 34-78) were included in the study and analyzed.
  • CONCLUSIONS: Epidermal growth factor receptor inhibitors' skin side effects have an important impact on quality of life in advanced colon cancer patients; symptoms scale is the most effect respect to emotional and functioning scales.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatology. 2002;204(1):43-9 [11834849.001]
  • [Cites] J Clin Oncol. 2010 Mar 10;28(8):1351-7 [20142600.001]
  • [Cites] J Invest Dermatol. 1997 Jan;108(1):103-7 [8980297.001]
  • [Cites] Arch Dermatol. 1997 Nov;133(11):1433-40 [9371029.001]
  • [Cites] Arch Dermatol. 1998 Apr;134(4):454-8 [9554297.001]
  • [Cites] Arch Dermatol. 2005 Mar;141(3):325-30 [15781673.001]
  • [Cites] Anticancer Drugs. 2006 Nov;17(10):1227-9 [17075324.001]
  • [Cites] Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S40-6 [17520580.001]
  • [Cites] Skin Pharmacol Physiol. 2007;20(5):260-2 [17641540.001]
  • [Cites] J Invest Dermatol. 2007 Dec;127(12):2726-39 [17989733.001]
  • [Cites] Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):10-6 [18154213.001]
  • [Cites] Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):34-6 [18154217.001]
  • [Cites] Clin Colorectal Cancer. 2008 Mar;7(2):144-8 [18501075.001]
  • [Cites] Cancer. 2009 Apr 1;115(7):1544-54 [19189371.001]
  • [Cites] Oncology (Williston Park). 2009 Feb;23(2):186-94 [19323301.001]
  • [Cites] Br J Dermatol. 2009 Apr;160(4):815-22 [19120325.001]
  • [Cites] J Clin Oncol. 2009 Apr 10;27(11):1822-8 [19273701.001]
  • [Cites] Support Care Cancer. 2010 Mar;18(3):329-34 [19484487.001]
  • [Cites] J Invest Dermatol. 1996 Nov;107(5):707-13 [8875954.001]
  • (PMID = 20398332.001).
  • [ISSN] 1477-7525
  • [Journal-full-title] Health and quality of life outcomes
  • [ISO-abbreviation] Health Qual Life Outcomes
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2861022
  •  go-up   go-down


50. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol; 2005 Dec 10;23(35):8950-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
  • An immunologic study of peripheral blood mononuclear cells (PBMCs) taken from 20 patients showed an enhanced proliferative response to colon carcinoma antigen and a significant reduction in suppressive regulatory T lymphocytes (CD4+CD25T-reg+).
  • CONCLUSION: The results show that our regimen has strong immunologic and antitumor activity in colorectal cancer patients and deserves to be investigated in phase III trials.
  • [MeSH-minor] Aged. Antigens, Neoplasm / immunology. Carcinoembryonic Antigen / immunology. Cytotoxicity, Immunologic / drug effects. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease Progression. Female. Flow Cytometry. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Infusions, Intravenous. Interleukin-2 / administration & dosage. Interleukin-2 / adverse effects. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. T-Lymphocytes, Regulatory / drug effects. T-Lymphocytes, Regulatory / immunology. Thymidylate Synthase / immunology. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061910.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Carcinoembryonic Antigen; 0 / Interleukin-2; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; B76N6SBZ8R / gemcitabine; EC 2.1.1.45 / Thymidylate Synthase; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


51. Takahashi S, Nagai K, Saito N, Konishi M, Nakagohri T, Gotohda N, Nishimura M, Yoshida J, Kinoshita T: Multiple resections for hepatic and pulmonary metastases of colorectal carcinoma. Jpn J Clin Oncol; 2007 Mar;37(3):186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Resections are effective for some patients with both hepatic and pulmonary metastases of colorectal cancer, but the best selection criteria for the resections and effective treatment for recurrence after the resections have not been determined.
  • METHODS: A retrospective analysis was performed for 30 consecutive patients who received aggressive multiple resections for both hepatic and pulmonary metastases of colorectal cancer.
  • Multivariate analyses revealed that primary colon cancer, stage IV in TNM classification and maximum size of hepatic tumor >3 cm at initial hepatectomy were poor prognostic factors, but several long-term survivors were observed even among patients with those factors.
  • CONCLUSIONS: Multiple resections for hepatic and pulmonary metastases of colorectal cancer are safe and effective.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Hepatectomy. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / surgery. Pneumonectomy. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472970.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


52. Iwashita Y, Sasaki A, Matsumoto T, Shibata K, Inomata M, Ohta M, Kitano S: Two-stage laparoscopic resection of colon cancer and metastatic liver tumour. J Minim Access Surg; 2005 Mar;1(1):37-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-stage laparoscopic resection of colon cancer and metastatic liver tumour.
  • We report herein the case of 70-year-old woman in whom colon cancer and a synchronous metastatic liver tumour were successfully resected laparoscopically.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2000 Apr;135(4):473-9; discussion 479-80 [10768715.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S306-11 [11821829.001]
  • [Cites] Surg Today. 2003;33(11):833-8 [14605955.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):213-6 [15036198.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • (PMID = 21234143.001).
  • [ISSN] 0972-9941
  • [Journal-full-title] Journal of minimal access surgery
  • [ISO-abbreviation] J Minim Access Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3016475
  • [Keywords] NOTNLM ; Colorectal cancer / laparoscopic hepatectomy / laparoscopy-assisted colectomy / metastatic liver tumour
  •  go-up   go-down


53. Shaikh A, Wiisanen ME, Gunderson HD, Leung N: Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab. Ann Pharmacother; 2009 Jul;43(7):1370-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE SUMMARY: A 77-year-old female with metastatic colon cancer presented with vomiting and diarrhea.
  • The patient had been diagnosed with stage IIIC (T3, N2, M0) colon cancer 18 months earlier and was initially treated with FOLFOX6 (regimen of oxaliplatin, fluorouracil, and leucovorin) after her hemicolectomy.
  • She did well until 10 months after her cancer diagnosis, when metastasis was discovered.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19584382.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


54. Cohen DJ, Hochster HS: Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer; 2007 Dec;7 Suppl 1:S21-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.
  • As a result of the development of novel chemotherapeutic drugs and targeted biologic agents, the treatment of colon cancer has changed significantly over the past 10 years.
  • Today, we have more active agents to use in colon cancer than ever before.
  • At present, patients with metastatic colon cancer routinely achieve a median survival time > 2 years.
  • Herein, we review the 2 main molecular targets of biologic therapy in colon cancer and examine the clinical evidence for regimens that inhibit angiogenesis and EGF receptor alone or in combination for newly diagnosed metastatic colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361803.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / Vascular Endothelial Growth Factor A; 04ZR38536J / oxaliplatin; 0H43101T0J / irinotecan; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 34
  •  go-up   go-down


55. Funaioli C, Pinto C, Di Fabio F, Santini D, Ceccarelli C, De Raffaele E, Fanti S, Castellucci P, Longobardi C, Buggi F, Martoni AA: 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy. Tumori; 2007 Nov-Dec;93(6):611-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy.
  • Around 20-30% of patients with hepatic metastasis from colorectal cancer can undergo liver resection, but the increased response rate obtained with the addition of monoclonal antibodies to chemotherapy regimens could result in a higher rate of liver surgery.
  • New specific studies are required to evaluate the imaging response in metastatic colorectal cancer patients especially after treatment with new, targeted agents.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338499.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 0 / Radiopharmaceuticals; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


56. Alessandro R, Seidita G, Flugy AM, Damiani F, Russo A, Corrado C, Colomba P, Gullotti L, Buettner R, Bruno L, De Leo G: Role of S128R polymorphism of E-selectin in colon metastasis formation. Int J Cancer; 2007 Aug 1;121(3):528-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of S128R polymorphism of E-selectin in colon metastasis formation.
  • The extravasation of cancer cells is a key step of the metastatic cascade.
  • Polymorphisms in genes encoding adhesion molecules can facilitate metastasis by increasing the strength of interaction between tumor and endothelial cells as well as impacting other properties of cancer cells.
  • We investigated the Ser128Arg (a561c at the nucleotide level) polymorphism in the E-selectin gene in patients with metastatic colon cancer and its functional significance.
  • Genotyping for a561c polymorphism was performed on 172 cancer patients and on an age-matched control population.
  • The colon cancer group was divided into groups with (M(+)) and without observable metastasis (M(-)).
  • For in vitro functional assays, Huvec transfected cells expressing wild-type (WT) or the S128R variant of E-selectin were established to study in vitro binding ability and signal transduction processes of T84 colon cancer cell line.
  • In vitro, S128R E-selectin transfected Huvec cells, supported increased adhesion as well as increased cellular signaling of T84 cancer cells compared to WT E-selectin and mock-transfected Huvec cells.
  • These findings suggest that the E-selectin S128R polymorphism can functionally affect tumor-endothelial interactions as well as motility and signaling properties of neoplastic cells that may modulate the metastatic phenotype.
  • [MeSH-major] Colonic Neoplasms / genetics. E-Selectin / genetics. Neoplasm Metastasis / genetics. Polymorphism, Genetic

  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17372905.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / E-Selectin; 452VLY9402 / Serine; 94ZLA3W45F / Arginine
  •  go-up   go-down


57. Foster JA, Salinas GD, Mansell D, Williamson JC, Casebeer LL: How does older age influence oncologists' cancer management? Oncologist; 2010;15(6):584-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How does older age influence oncologists' cancer management?
  • BACKGROUND: Over half of new cancer cases occur in patients aged > or = 65 years.
  • Many older patients can benefit from intensive cancer therapies, yet evidence suggests that this population is undertreated.
  • METHODS: To assess preferences and influential factors in geriatric cancer management, practicing U.S. medical oncologists completed a survey containing four detailed vignettes exploring colon, breast, lung, and prostate cancer treatment.
  • For a woman with metastatic colon cancer (Eastern Cooperative Oncology Group [ECOG] score, 1) for whom chemotherapy was recommended, nearly all oncologists chose an intensive regimen if the patient's age was 63; but if her age was 85, one fourth of the oncologists chose a less intensive treatment.
  • Likewise, for stage IIA breast cancer (ECOG score, 0), 93% recommended intensive adjuvant treatment for a previously healthy patient aged 63; but only 66% said they would do so if the patient's age was 75.
  • CONCLUSIONS: Advanced age can deter oncologists from choosing intensive cancer therapy, even if patients are highly functional and lack comorbidities.
  • Education on tailoring cancer treatment and a greater use of comprehensive geriatric assessment may reduce cancer undertreatment in the geriatric population.


58. Lee HJ, Lee EK, Lee KJ, Hong SW, Yoon Y, Kim JS: Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer; 2006 May 15;118(10):2490-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells.
  • It is thought to play a role in regulating cellular growth since its expression is highly upregulated in a variety of proliferative cells such as cancer cells.
  • Here, we found NGAL expression in highly and poorly metastatic colon cancer cell lines of the same genetic origin correlated inversely with the metastatic potential of these cells, which suggests NGAL participates in the metastatic process.
  • To explore the role NGAL plays in tumor growth and metastasis, the KM12SM human colon cancer cell line, which is highly metastatic while showing decreased NGAL expression, was genetically manipulated to overexpress NGAL.
  • Ectopic expression of NGAL in the colon cancer cells had little effect on the growth and viability of the tumor cells both in vitro and in vivo.
  • However, NGAL expression not only suppressed the ability of the colon carcinoma cells to invade Matrigel in vitro, it also substantially inhibited liver metastasis in an experimental animal model.
  • Collectively, these results indicate that NGAL may be a candidate metastasis suppressor in colon cancer cells.
  • [MeSH-minor] Blotting, Western. Cell Proliferation. Collagen. Drug Combinations. Flow Cytometry. Gene Expression Profiling. Humans. Laminin. Lipocalins. Neoplasm Invasiveness. Proteoglycans. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16381001.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Drug Combinations; 0 / LCN2 protein, human; 0 / Laminin; 0 / Lipocalins; 0 / Proteoglycans; 0 / Proto-Oncogene Proteins; 119978-18-6 / matrigel; 9007-34-5 / Collagen
  •  go-up   go-down


59. Heinzerling JH, Huerta S: Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg; 2006 Sep-Oct;63(5):334-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
  • Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer.
  • [MeSH-major] Abdomen, Acute / chemically induced. Adenocarcinoma / drug therapy. Angiogenesis Inhibitors / adverse effects. Antibodies, Monoclonal / adverse effects. Intestinal Perforation / chemically induced. Neoplasm Recurrence, Local / drug therapy. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16971205.001).
  • [ISSN] 0149-7944
  • [Journal-full-title] Current surgery
  • [ISO-abbreviation] Curr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


60. Tsujie M, Fujiwara S, Kida H, Hayashi N, Fukuchi S, Yoshida T, Ebisui C, Sakita I, Hasuike Y, Fujimoto T: [A case of metastatic colon cancer treated with oxaliplatin combination chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1774-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic colon cancer treated with oxaliplatin combination chemotherapy].
  • A 77-year-old male had been operated for ascending colon cancer with liver metastases.
  • We conclude that the oxaliplatin-based chemotherapy may be useful for patients suffering 5-FU and CPT-11 resistant metastatic colorectal cancer in Japan.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315937.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 039LU44I5M / Floxuridine; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; V1JK16Y2JP / doxifluridine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


61. Wolfsen HC, Hemminger LL: Salvage photodynamic therapy for persistent esophageal cancer after chemoradiation therapy. Photodiagnosis Photodyn Ther; 2006 Mar;3(1):11-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage photodynamic therapy for persistent esophageal cancer after chemoradiation therapy.
  • BACKGROUND: Locally advanced esophageal cancer may not be completely eradicated after chemoradiation therapy (CRT) and further treatment options are limited.
  • After upper endoscopy with biopsies documented neoplasm after CRT, patients were evaluated with contrast-enhanced computed tomography of the chest and abdomen as well as endoscopic ultrasound to confirm persistence/recurrence of only mucosal disease.
  • The other five patients treated for Barrett's carcinoma have remained disease free although one had died 33 months from metastatic colon cancer.
  • CONCLUSION: In selected patients, PDT may be useful in the treatment of persistent/recurrent mucosal esophageal cancer after incomplete response to CRT.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25049021.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


62. Shin KS, Hong SB, Son BR: [A Case of Catheter-Related Bacteremia by Arthrobacter woluwensis.]. Korean J Lab Med; 2006 Apr;26(2):103-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arthrobacter woluwensis, a catalase-positive coryneform bacterium recognized as an opportunistic pathogen, was repeatedly isolated from the blood of a 56-year-old male patient with metastatic colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156709.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


63. Guess CM, Lafleur BJ, Weidow BL, Quaranta V: A decreased ratio of laminin-332 beta3 to gamma2 subunit mRNA is associated with poor prognosis in colon cancer. Cancer Epidemiol Biomarkers Prev; 2009 May;18(5):1584-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A decreased ratio of laminin-332 beta3 to gamma2 subunit mRNA is associated with poor prognosis in colon cancer.
  • Herein, we test the hypothesis that mRNA changes in one or more Ln-332 encoding genes can be used to distinguish between early- and advanced-stage cancer specimens and shed light on mechanistic questions raised by previous studies.
  • Statistical analyses of human microarray data from the publicly available expression project in Oncology (expO) dataset, including examination of the distributions of Ln-332 subunit mRNA levels, identified a significant decrease in the Ln-332 beta3:gamma2 mRNA ratio between normal (n = 10) and early-stage colon cancer (n = 29) specimens.
  • The beta3:gamma2 ratio was further decreased in metastatic colon cancer (n = 41) compared with early-stage samples.
  • Our findings raise the possibility that Ln-332 gamma2 may be a therapeutic target against metastatic colon cancer because a lowered beta3:gamma2 ratio would reduce expression of heterotrimeric Ln-332 and increase monomeric gamma2 secretion.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1996 Mar 5;35(9):2885-93 [8608125.001]
  • [Cites] J Cell Biol. 1996 Mar;132(6):1189-98 [8601594.001]
  • [Cites] J Pathol. 1996 Nov;180(3):290-4 [8958807.001]
  • [Cites] J Pathol. 1998 May;185(1):44-52 [9713359.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2315-21 [10357399.001]
  • [Cites] Matrix Biol. 1999 Feb;18(1):5-17 [10367727.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):893-8 [15821121.001]
  • [Cites] Hum Pathol. 2005 May;36(5):522-30 [15948119.001]
  • [Cites] Oncology. 2005;69(1):71-80 [16103736.001]
  • [Cites] J Dermatol Sci. 2005 Oct;40(1):11-20 [15993569.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1375-83 [16285938.001]
  • [Cites] Cancer Sci. 2006 Feb;97(2):91-8 [16441418.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5251-7 [16707450.001]
  • [Cites] Head Neck. 2006 Aug;28(8):740-9 [16649214.001]
  • [Cites] Methods Enzymol. 2006;410:3-28 [16938544.001]
  • [Cites] OMICS. 2006 Fall;10(3):358-68 [17069513.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):370-80 [17457303.001]
  • [Cites] BMC Bioinformatics. 2007;8:194 [17559689.001]
  • [Cites] BMC Genomics. 2008;9:69 [18254958.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5596-601 [10554040.001]
  • [Cites] Cell Tissue Res. 2000 Apr;300(1):129-37 [10805082.001]
  • [Cites] J Cell Biol. 2001 May 14;153(4):835-50 [11352943.001]
  • [Cites] Oncology. 2002;62(4):318-26 [12138239.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):498-505 [12492492.001]
  • [Cites] J Cell Biol. 2003 Apr 14;161(1):197-209 [12695504.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3684-91 [14506159.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):277-86 [15339047.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18 Suppl):5054s-5059s [1884381.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]
  • [Cites] J Biol Chem. 1994 Jul 22;269(29):19167-75 [8034675.001]
  • [Cites] J Biol Chem. 1994 Dec 2;269(48):30386-92 [7982952.001]
  • [Cites] J Biol Chem. 1995 Feb 17;270(7):3292-8 [7852414.001]
  • [Cites] J Biol Chem. 1995 Oct 6;270(40):23496-503 [7559513.001]
  • [Cites] Genomics. 1996 Feb 15;32(1):54-64 [8786121.001]
  • (PMID = 19383890.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U54 CA113007; United States / NCI NIH HHS / CA / R01 CA047858; United States / NCI NIH HHS / CA / R01 CA047858-19; United States / NCI NIH HHS / CA / U54 CA113007-04S1; United States / NCI NIH HHS / CA / CA113007-04S1; United States / NCI NIH HHS / CA / CA047858-19; United States / NCI NIH HHS / CA / 3U54CA11300702S1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / RNA, Messenger; 0 / kalinin
  • [Other-IDs] NLM/ NIHMS200776; NLM/ PMC2869450
  •  go-up   go-down


64. Tsouma A, Aggeli C, Lembessis P, Zografos GN, Korkolis DP, Pectasides D, Skondra M, Pissimissis N, Tzonou A, Koutsilieris M: Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World J Gastroenterol; 2010 Dec 21;16(47):5965-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients.
  • AIM: To develop a multiplex reverse transcription polymerase chain reaction (RT-PCR) method detecting circulating tumor cells in the peripheral blood of colorectal cancer (CRC) patients.
  • The analysis involved determining the detection rates of CEA, CK20 and EGFR transcripts vs disease stage and overall survival.
  • The increasing number of positive detections for CEA, CK20 and EGFR transcripts in each blood sample was positively correlated with Astler-Coller disease stage (P < 0.001) and preoperative serum levels of CEA (P = 0.029) in CRC patients.
  • CONCLUSION: These data suggest that multiplex RT-PCR assay can provide useful information concerning disease stage and overall survival of CRC patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2005 Apr;29(4):422-8 [15770378.001]
  • [Cites] World J Surg. 2007 Dec;31(12):2329-34 [17914651.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4158-63 [10632355.001]
  • [Cites] Lancet. 2000 Jan 29;355(9201):395-9 [10665570.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1439-44 [10778975.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):58-65 [10862196.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(13 Spec No):1681-94 [10959054.001]
  • [Cites] Clin Exp Metastasis. 1999;17(10):823-30 [11089880.001]
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):65-73 [11121864.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2523-32 [11289125.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):577-83 [11297251.001]
  • [Cites] Exp Mol Med. 2001 Mar 31;33(1):8-14 [11322488.001]
  • [Cites] Int J Colorectal Dis. 2001 Jun;16(3):141-6 [11459287.001]
  • [Cites] J Clin Oncol. 2001 Oct 1;19(19):3951-9 [11579116.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8845-50 [11751407.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4080-5 [11751505.001]
  • [Cites] Gut. 2002 Apr;50(4):530-4 [11889075.001]
  • [Cites] Mol Pathol. 2002 Jun;55(3):156-63 [12032226.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):217-22 [12469172.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):425-30 [12527944.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):3135-42 [16080577.001]
  • [Cites] Oncol Rep. 2005 Nov;14(5):1199-202 [16211285.001]
  • [Cites] J Mol Diagn. 2005 Nov;7(5):631-7 [16258162.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):297-306 [16391782.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):411-20 [16391796.001]
  • [Cites] J Mol Diagn. 2006 Feb;8(1):105-12 [16436641.001]
  • [Cites] Int J Clin Oncol. 2006 Oct;11(5):385-9 [17058136.001]
  • [Cites] Clin Chem Lab Med. 2006;44(12):1403-9 [17163814.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1092-8 [17200912.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2406-13 [17406027.001]
  • [Cites] Dis Colon Rectum. 2007 Aug;50(8):1188-203 [17436048.001]
  • [Cites] Clin Chem Lab Med. 2007;45(11):1488-94 [17924845.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):1040-6 [18043108.001]
  • [Cites] J Surg Oncol. 2007 Dec 15;96(8):693-703 [18081153.001]
  • [Cites] Cancer Lett. 2008 May 18;263(2):267-79 [18262345.001]
  • [Cites] Cell Oncol. 2008;30(6):463-71 [18936523.001]
  • [Cites] Jpn J Clin Oncol. 2008 Nov;38(11):770-6 [18845519.001]
  • [Cites] Clin Chem Lab Med. 2009;47(1):1-11 [19055471.001]
  • [Cites] Anticancer Res. 2008 Nov-Dec;28(6B):3945-60 [19192655.001]
  • [Cites] Mol Med. 2009 Mar-Apr;15(3-4):101-14 [19081770.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):272-9 [19103472.001]
  • [Cites] Cancer. 2010 Jun 15;116(12):2913-21 [20336782.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2678-82 [12855647.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):989-95 [12905553.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):324-30; discussion 330-1 [14501498.001]
  • [Cites] Surg Endosc. 2004 Apr;18(4):587-91 [14735340.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Dis Colon Rectum. 1980 Apr;23(3):141-4 [7379666.001]
  • [Cites] Ann Intern Med. 1986 Jan;104(1):66-73 [3510056.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):567-80 [1696264.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):427-47 [1371204.001]
  • [Cites] Differentiation. 1993 Jun;53(2):75-93 [8359595.001]
  • [Cites] Blood. 1997 Jan 1;89(1):337-44 [8978310.001]
  • [Cites] Exp Hematol. 1997 Jan;25(1):57-65 [8989908.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):55-9 [9208961.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):343-8 [9516921.001]
  • [Cites] Int J Cancer. 1998 Jun 19;79(3):288-93 [9645353.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2632-40 [9704713.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3037-43 [9865918.001]
  • [Cites] J Mol Med (Berl). 2004 Nov;82(11):768-74 [15490093.001]
  • [Cites] World J Gastroenterol. 2005 Jan 21;11(3):436-8 [15637763.001]
  • [Cites] Clin Exp Metastasis. 2004;21(6):495-505 [15679047.001]
  • [Cites] Int J Colorectal Dis. 2005 Mar;20(2):137-46 [15459772.001]
  • [Cites] Crit Rev Clin Lab Sci. 2005;42(2):155-96 [15941083.001]
  • (PMID = 21157973.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-20; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC3007112
  •  go-up   go-down


65. Ohsawa I, Murakami T, Uemoto S, Kobayashi E: In vivo luminescent imaging of cyclosporin A-mediated cancer progression in rats. Transplantation; 2006 Jun 15;81(11):1558-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo luminescent imaging of cyclosporin A-mediated cancer progression in rats.
  • BACKGROUND: Immunosuppressed individuals undergoing organ transplantation are at increased risk of recurrences of initial cancers, although how immunosuppressive therapy increases early cancer metastasis remains unclear.
  • METHODS: The metastatic fate of luciferase-expressing rat metastatic colon cancer cells (luc-RCN-H4) injected intravenously into the liver of syngeneic and allogeneic rats was examined in the presence of the immunosuppressant cyclosporin A (CsA) by in vivo luminescent technique.
  • CONCLUSIONS: Whereas the chemokine receptor expression by cancer cells is implicated with early organotropic dissemination even under CsA-mediated immune suppression, rather, CsA enhances the late-phase progression after tumor adhesion through TGF-beta1 expression.
  • [MeSH-minor] Animals. Benzamides / pharmacology. Blotting, Western. Cell Adhesion. Cell Line, Tumor. Cell Movement / drug effects. Dioxoles / pharmacology. Disease Progression. Gene Expression Regulation, Neoplastic / drug effects. Killer Cells, Natural / drug effects. Killer Cells, Natural / pathology. Liver Neoplasms / genetics. Liver Neoplasms / immunology. Liver Neoplasms / secondary. Luminescence. Lymphatic Metastasis / immunology. Male. Neoplasm Metastasis / pathology. Rats. Rats, Inbred F344. Receptors, Chemokine / analysis. Receptors, Chemokine / genetics. Reperfusion Injury / pathology. Reverse Transcriptase Polymerase Chain Reaction. Transforming Growth Factor beta / analysis. Transforming Growth Factor beta / genetics. Transforming Growth Factor beta1

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770245.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide; 0 / Benzamides; 0 / Dioxoles; 0 / Receptors, Chemokine; 0 / Tgfb1 protein, rat; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


66. Testini M, Lissidini G, Gurrado A, Lastilla G, Ianora AS, Fiorella R: Acute airway failure secondary to thyroid metastasis from renal carcinoma. World J Surg Oncol; 2008;6:14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Secondary involvement of the thyroid gland by malignant metastases is uncommon.
  • Only two cases of metastatic colon cancer and one case of metastatic meningioma requiring emergency thyroidectomy for acute respiratory failure are reported in the literature.

  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microsurgery. 2004;24(1):39-42 [14748023.001]
  • [Cites] Del Med J. 2003 Aug;75(8):285-8 [12971227.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 1996;117(3):237-9 [9102733.001]
  • [Cites] Endocr Pract. 2001 Sep-Oct;7(5):370-4 [11585373.001]
  • [Cites] Thyroid. 2001 Sep;11(9):883-8 [11575859.001]
  • [Cites] Ann Acad Med Singapore. 2004 Jan;33(1):100-2 [15008573.001]
  • [Cites] Acta Pathol Microbiol Scand Suppl. 1977;(260):1-235 [269649.001]
  • [Cites] Cancer. 1989 May 1;63(9):1810-5 [2649228.001]
  • [Cites] Arch Intern Med. 1989 Jul;149(7):1575-7 [2742431.001]
  • [Cites] Am J Surg. 1989 Oct;158(4):378-80; discussion 380-1 [2802045.001]
  • [Cites] Ear Nose Throat J. 1992 Aug;71(8):350, 353-5 [1396183.001]
  • [Cites] J Laryngol Otol. 1996 Dec;110(12):1176-8 [9015439.001]
  • [Cites] Thyroid. 1994 Fall;4(3):297-300 [7833666.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):1869-78 [12404280.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Apr;120(4):427-30 [8166974.001]
  • [Cites] Aust N Z J Surg. 1994 Apr;64(4):286-8 [8147789.001]
  • [Cites] Am Surg. 1994 Aug;60(8):586-91 [8030813.001]
  • (PMID = 18252002.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2254624
  •  go-up   go-down


67. Marshall JL: More fanfare for metastatic colon cancer resections. Gastrointest Cancer Res; 2007 Jan;1(1):28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] More fanfare for metastatic colon cancer resections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262700.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2632518
  •  go-up   go-down


68. Ban D, Sakamoto Y, Shimada K, Kosuge T, Sekine S, Taniguchi H: Erythropoietin production caused by metastatic colon cancer. Int J Colorectal Dis; 2010 Mar;25(3):405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythropoietin production caused by metastatic colon cancer.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19756658.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 11096-26-7 / Erythropoietin
  •  go-up   go-down


69. Errante D, Bernardi D, Bianco A, Zanatta N, Salvagno L: Recurrence of exhausting hiccup in a patient treated with chemotherapy for metastatic colon cancer. Gut; 2005 Oct;54(10):1503-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of exhausting hiccup in a patient treated with chemotherapy for metastatic colon cancer.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Hiccups.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 May 15;94(10):772 [12011230.001]
  • [Cites] Am J Hematol. 2004 Nov;77(3):319-20 [15495237.001]
  • [Cites] Brain. 1970;93(4):851-72 [5490279.001]
  • [Cites] Neurology. 1961 Feb;11:109-15 [13698714.001]
  • [Cites] Laryngoscope. 1980 Oct;90(10 Pt 1):1612-8 [7421372.001]
  • [Cites] Ann Intern Med. 1986 Jan;104(1):58-9 [3510055.001]
  • [Cites] Cancer. 1998 Jan 15;82(2):412-4 [9445200.001]
  • [Cites] J Neural Transm. 1978;42(1):63-71 [641544.001]
  • (PMID = 16162960.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiemetics; 0 / Antineoplastic Agents, Hormonal; 7S5I7G3JQL / Dexamethasone
  • [Other-IDs] NLM/ PMC1774708
  •  go-up   go-down


70. Hofmann LJ, Lee S, Waddell B, Davis KG: Effect of race on colon cancer treatment and outcomes in the Department of Defense healthcare system. Dis Colon Rectum; 2010 Jan;53(1):9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of race on colon cancer treatment and outcomes in the Department of Defense healthcare system.
  • PURPOSE: The increase in mortality noted in African Americans with colon cancer is attributed to advanced stage at presentation and disparities in treatment received.
  • The aim of this study was to assess the influence of race on the treatments and survival of colon cancer patients in an equal-access healthcare system.
  • METHODS: This retrospective cohort study included African American and white patients with colon cancer treated at Department of Defense facilities.
  • Disease stage, surgery performed, chemotherapy used, and overall survival were evaluated.
  • RESULTS: Of the 6958 colon cancer patients identified, 1115 were African American.
  • African Americans presented more frequently with stage IV disease, 23% vs 17% for whites (P < .001).
  • There was no difference in the use of systemic chemotherapy for stage III colon cancer (73.5% for African Americans vs 72.2% for whites; chi2, P > .05) or stage IV colon cancer (56.3% for African Americans vs 54.4% for whites; chi2, P > .05).
  • After adjusting for gender, age, tumor grade, and stage, African American race was not a risk factor for survival in Cox proportional hazard analysis (hazard ratio, 0.981; 95% confidence interval, 0.888-1.084).
  • African American patients undergo surgery and chemotherapy is administered at rates equal to whites for all stages of colon cancer.

  • MedlinePlus Health Information. consumer health - African American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010344.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Shao YY, Hong RL: Fatal thrombocytopenia after oxaliplatin-based chemotherapy. Anticancer Res; 2008 Sep-Oct;28(5B):3115-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 64-year-old patient with metastatic colon cancer was admitted for his 24th course of chemotherapy with oxaliplatin and 24-hour infusion of fluorouracil and leucovorin.

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031966.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


72. Odoux C, Fohrer H, Hoppo T, Guzik L, Stolz DB, Lewis DW, Gollin SM, Gamblin TC, Geller DA, Lagasse E: A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res; 2008 Sep 1;68(17):6932-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A stochastic model for cancer stem cell origin in metastatic colon cancer.
  • Human cancers have been found to include transformed stem cells that may drive cancer progression to metastasis.
  • Here, we report that metastatic colon cancer contains clonally derived tumor cells with all of the critical properties expected of stem cells, including self-renewal and the ability to differentiate into mature colon cells.
  • Additionally, when injected into mice, these cells initiated tumors that closely resemble human cancer.
  • Karyotype analyses of parental and clonally derived tumor cells expressed many consistent (clonal) along with unique chromosomal aberrations, suggesting the presence of chromosomal instability in the cancer stem cells.
  • Thus, this new model for cancer origin and metastatic progression includes features of both the hierarchical model for cancerous stem cells and the stochastic model, driven by the observation of chromosomal instability.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5 [11121071.001]
  • [Cites] Int J Epidemiol. 2006 Oct;35(5):1151-9 [16987840.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):818-22 [11221861.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2055-64 [11493641.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):10-1 [12509774.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):695-701 [12951588.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Immunology. 1975 Jun;28(6):1135-48 [1079511.001]
  • [Cites] Methods Cell Biol. 1976;13:29-83 [177845.001]
  • [Cites] J Cell Biol. 1984 Mar;98(3):1026-32 [6699079.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1359-63 [2449944.001]
  • [Cites] Blood. 1989 Dec;74(8):2755-63 [2819245.001]
  • [Cites] Blood. 1991 Aug 15;78(4):945-52 [1678290.001]
  • [Cites] Blood. 1991 Nov 15;78(10):2527-33 [1824250.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Cell Res. 2007 Jan;17(1):3-14 [17179981.001]
  • [Cites] Br J Cancer. 2007 Feb 26;96(4):677-8; author reply 679-80 [17285131.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S71-80 [17382016.001]
  • [Cites] J Natl Cancer Inst. 2007 May 2;99(9):680-93 [17470736.001]
  • [Cites] Clin Colorectal Cancer. 2007 May;6(7):508-15 [17553199.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Gene Ther. 2008 Jan;15(2):136-42 [17989699.001]
  • [Cites] J Pathol. 1993 Aug;170(4):441-50 [8410493.001]
  • [Cites] Gastroenterology. 1994 Nov;107(5):1352-63 [7926500.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3653-9 [7524745.001]
  • [Cites] Differentiation. 1996 Jul;60(4):259-68 [8765056.001]
  • [Cites] J Clin Pathol. 1996 Jul;49(7):560-4 [8813954.001]
  • [Cites] Semin Surg Oncol. 1996 Jul-Aug;12(4):219-52 [8829283.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):1137-41 [9378551.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5):556-60 [10528904.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):338-41 [15549096.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):33-42 [15613286.001]
  • [Cites] J Cell Mol Med. 2005 Jan-Mar;9(1):11-24 [15784161.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Nat Med. 2006 Mar;12(3):296-300 [16520777.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1111-5 [16564000.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):449-58 [16723991.001]
  • [Cites] Hepatology. 2001 Feb;33(2):363-78 [11172338.001]
  • (PMID = 18757407.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NIDCR NIH HHS / DE / R01 DE014729-05; None / None / / R01 DE014729-05; United States / NIDCR NIH HHS / DE / R01DE14729; United States / NIDCR NIH HHS / DE / R01 DE014729-04; United States / NCI NIH HHS / CA / CA047904-169019; United States / NCI NIH HHS / CA / P30 CA047904; United States / NCI NIH HHS / CA / CA047904-159019; United States / NCI NIH HHS / CA / P30CA047904; United States / NCI NIH HHS / CA / P30 CA047904-159019; United States / NIDCR NIH HHS / DE / R01 DE014729; United States / NCI NIH HHS / CA / P30 CA047904-169019; United States / NIDCR NIH HHS / DE / DE014729-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS57086; NLM/ PMC2562348
  •  go-up   go-down


73. Rengen MR, De J, Kott MM, Adler DG: Endoscopic ultrasound diagnosis of colon cancer metastatic to the pancreas. Endoscopy; 2006 Aug;38(8):853
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound diagnosis of colon cancer metastatic to the pancreas.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16862530.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. Xu F, Ye YJ, Cui ZR, Wang S: Allogeneic dendritomas induce anti-tumour immunity against metastatic colon cancer. Scand J Immunol; 2005 Apr;61(4):364-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic dendritomas induce anti-tumour immunity against metastatic colon cancer.
  • Colon cancer (CC) is one of the most common malignancies in the Western world.
  • Although surgical resection is the first choice worldwide, at this point an effective approach for the treatment of patients with metastasis and cancer recurrence post-operation has not yet been found.
  • The aim of this study was to investigate the role of the allogeneic dendritomas from fusion of dendritic cells (DC) and metastatic CC cells in the activation of anti-tumour immunity against metastatic CC.
  • Dendritomas were generated by fused allogeneic human peripheral blood DC with metastatic CC cells using 50% polyethylene glycol.
  • These results demonstrate that allogeneic dendritomas activate T-cell responses against metastatic CC cells.
  • [MeSH-minor] Cell Fusion. Flow Cytometry. Humans. Immunophenotyping. Lymphocyte Activation. Neoplasm Metastasis. Polyethylene Glycols. T-Lymphocytes, Cytotoxic / cytology. T-Lymphocytes, Cytotoxic / immunology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853920.001).
  • [ISSN] 0300-9475
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


75. Busić Z, Cupurdija K, Kolovrat M, Cavka V, Cavka M, Patrlj L, Servis D, Kvesić A: Isolated splenic metastasis from colon cancer--case report and literature review. Coll Antropol; 2010 Mar;34 Suppl 1:287-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic metastasis from colon cancer--case report and literature review.
  • In this paper we present a case of 70-year-old man with no history of previous diseases who was first operated under the diagnosis of acute abdomen revealing perforated colon tumor of splenic flexure with no metastases at that time.
  • Primary tumor was classified as Dukes (Astler-Coller)-C2, T4NIMO.
  • The latest follow up, a year after diagnosis of metastasis showed no signs of cancer disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20402335.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


76. Matsuo Y, Sawai H, Ma J, Xu D, Ochi N, Yasuda A, Takahashi H, Funahashi H, Takeyama H: IL-1alpha secreted by colon cancer cells enhances angiogenesis: the relationship between IL-1alpha release and tumor cells' potential for liver metastasis. J Surg Oncol; 2009 May 1;99(6):361-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IL-1alpha secreted by colon cancer cells enhances angiogenesis: the relationship between IL-1alpha release and tumor cells' potential for liver metastasis.
  • BACKGROUND AND OBJECTIVES: Interleukin (IL)-1alpha plays an important role in colon cancer progression and angiogenesis.
  • We here asked whether IL-1alpha derived from cancer cells modulates vascular endothelial cell growth, migration and tubule formation.
  • METHODS: The existence of IL-1alpha mRNA and protein in colon cancer cell lines (WiDr, HT-29, Caco-2, COLO 320) were investigated with RT-PCR and ELISA.
  • RESULTS: IL-1alpha mRNA and protein were detected in highly metastatic colon cancer cells (WiDr and HT-29).
  • CONCLUSION: Based on these findings, we conclude that colon cancer cell-derived IL-1alpha up-regulates angiogenesis by modulating stromal cells within the tumor cells' microenvironment.
  • [MeSH-minor] Caco-2 Cells. Cell Line, Tumor. Cell Proliferation. Enzyme-Linked Immunosorbent Assay. Humans. Neoplasm Invasiveness. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19204921.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1alpha; 0 / RNA, Messenger
  •  go-up   go-down


77. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Chun HK, Lee WY, Park YS: The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Med Oncol; 2010 Dec;27(4):1277-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
  • Colon cancer with DNA mismatch repair (MMR) defects reveals distinct clinical and pathologic features, including a better prognosis but reduced response to 5-fluorouracil (5-FU)-based chemotherapy.
  • A current standard treatment for recurrent or metastatic colon cancer uses capecitabine plus oxaliplatin (CAPOX), or continuous-infusion fluorouracil plus oxaliplatin (FOLFOX).
  • This study investigated the effect of MMR status on the treatment outcomes for CAPOX and FOLFOX as first-line combination chemotherapy in recurrent or metastatic colon cancer.
  • We analyzed 171 patients who had been treated with CAPOX or FOLFOX as first-line combination chemotherapy in recurrent or metastatic colon adenocarcinoma between February 2004 and July 2008.
  • The incidence of colon cancer with MMR defect was 10/171 (6%).
  • Colon cancers with MMR defect (MSI-H and/or MMR-D) are more commonly located in proximal to the splenic flexure (p=0.03).
  • The MMR status did not significantly influence the overall response (p=0.95) to first-line CAPOX or FOLFOX treatment in patients with recurrent or metastatic colon cancer.
  • According to the MMR status, there was no significant difference for PFS (p=0.50) and OS (p=0.47) in patients with recurrent or metastatic colon cancer treated with first-line CAPOX or FOLFOX.
  • In colon cancers with MMR defect, there was no significant difference for PFS (p=0.48) and OS (p=0.56) between CAPOX and FOLFOX as first-line combination chemotherapy.
  • The MMR status does not predict the effect of oxaliplatin-based combination chemotherapy as 1st line in recurrent or metastatic colon cancers.
  • CAPOX in the first-line treatment of recurrent or metastatic colon cancer with MMR intacts showed a superior OS compared with FOLFOX unlike colon cancer with MMR defects.
  • [MeSH-major] Adenocarcinoma / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / genetics. DNA Mismatch Repair / drug effects. Microsatellite Instability / drug effects. Neoplasm Recurrence, Local / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Follow-Up Studies. Humans. Immunoenzyme Techniques. Infusions, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Polymerase Chain Reaction. Prognosis. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2006 Apr;93(4):395-406 [16555243.001]
  • [Cites] Int J Colorectal Dis. 2008 Nov;23(11):1033-9 [18594845.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4224-30 [17548839.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1735-43 [11919229.001]
  • [Cites] Target Oncol. 2009 Jan;4(1):57-62 [19343302.001]
  • [Cites] Korean J Intern Med. 2005 Jun;20(2):116-22 [16134765.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):862-76 [12198712.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6039-44 [11085525.001]
  • [Cites] Oncogene. 1999 Apr 8;18(14 ):2335-41 [10327053.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6424-8 [8341649.001]
  • [Cites] Gut. 1998 May;42(5):673-9 [9659163.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1841-5 [9157971.001]
  • [Cites] Gastroenterology. 2008 Sep;135(3):770-80 [18619459.001]
  • [Cites] Surgery. 2002 Feb;131(2):190-7 [11854698.001]
  • [Cites] Oncogene. 1997 Jul 3;15(1):45-52 [9233776.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4553-60 [16002847.001]
  • [Cites] Science. 1993 May 7;260(5109):812-6 [8484121.001]
  • [Cites] Anticancer Res. 2009 May;29(5):1615-20 [19443375.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Clin Colorectal Cancer. 2007 Mar;6(6):433-5 [17531106.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] Br J Cancer. 2009 Jan 27;100(2):266-73 [19165197.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1409-18 [17426704.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):767-72 [17228023.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4C):2715-9 [17695437.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] J Surg Oncol. 2004 Dec 15;88(4):261-6 [15565587.001]
  • [Cites] J Biol Chem. 2000 Feb 11;275(6):3922-30 [10660545.001]
  • [Cites] Lancet. 2002 Nov 2;360(9343):1381-91 [12423985.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1374-81 [8640828.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12 ):6870-5 [9618505.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3087-90 [8674066.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):1121-7 [11238060.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):476-87 [15689586.001]
  • [Cites] Lancet Oncol. 2002 Feb;3(2):83-8 [11905459.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3579-85 [9721864.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4881-6 [8895738.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Feb;2(2):147-56 [15017620.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):434-44 [15668707.001]
  • (PMID = 19949897.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


78. Wakahara T, Tsukamoto T, Kitamura S, Watanabe A, Tsujimura T, Nakamura Y, Toyokawa A, Onishi N, Hamabe Y, Mukai H, Teramura K: Metastatic colon cancer from intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg; 2005;12(5):415-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic colon cancer from intrahepatic cholangiocarcinoma.
  • A 62-year-old man had been followed because of an elevated serum level of carcinoembryonic antigen without the detection of any cancer lesions.
  • However, there was a sudden increase in the serum level of carcinoembryonic antigen, and abdominal imagings showed a hepatic tumor with peripheral intrahepatic bile duct dilatation, and a submucosal tumor at the sigmoid colon with intact mucosa.
  • Histopathological findings showed that the hepatic tumor had perineural invasion, suggesting an intrahepatic cholangiocarcinoma, and that the colon tumor infiltrated the submucosa, while its mucosa was intact.
  • These findings suggested intrahepatic cholangiocarcinoma with metastatic sigmoid colon cancer.

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258812.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


79. Hanna WC, Ponsky TA, Trachiotis GD, Knoll SM: Colon cancer metastatic to the lung and the thyroid gland. Arch Surg; 2006 Jan;141(1):93-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer metastatic to the lung and the thyroid gland.
  • The clinical diagnosis of primary thyroid cancer is uncommon, constituting 1.5% of all cancers in the United States.
  • Clinically diagnosed metastatic cancer to the thyroid gland is rare.
  • Colon cancer is one of the most common cancers in the United States, with a high propensity to metastasize; 30% to 40% of patients have metastatic disease at the initial diagnosis.
  • The most common sites of metastasis from colon cancer are the regional lymph nodes, the liver, the lung, and the peritoneum.
  • Colon cancer metastasis to the thyroid gland is rare, with only a few reported cases, mainly in the pathology literature.
  • These cases describe metastasis from colon cancer to the thyroid gland that became apparent years after the initial diagnosis of colon cancer and were usually associated with dissemination to the liver, the lung, or both.
  • We report a case of colonic adenocarcinoma metastatic to the thyroid gland and lung without involvement of the liver.


80. Guzman L, Kozloff M, Wallace J, Starr A: Cutaneous eruption related to human epidermal growth factor receptor inhibitors in stage IV colon cancer. Clin J Oncol Nurs; 2009 Oct;13(5):491-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous eruption related to human epidermal growth factor receptor inhibitors in stage IV colon cancer.

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793706.001).
  • [ISSN] 1538-067X
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


81. Czito BG, Bendell J, Willett CG: Radiation therapy for resectable colon cancer. Is there a role in the modern chemotherapy era? Oncology (Williston Park); 2006 Feb;20(2):179-87; discussion 187-8, 192
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy for resectable colon cancer. Is there a role in the modern chemotherapy era?
  • Colon cancer is a major public health problem.
  • For patients with early-stage disease, surgery results in excellent survival rates.
  • With the advent of novel and more effective systemic therapies for metastatic colon cancer, current and future clinical research will address the efficacy of these agents in the adjuvant setting.
  • Adjuvant radiation therapy should be considered in patients with colon cancer at high risk for local failure.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16562650.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


82. Garibaldi DC, Adler RA: Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Ophthal Plast Reconstr Surg; 2007 Jan-Feb;23(1):62-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab.
  • Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) of cancer cells expressing EGFR and prevents dimerization and downstream cell signaling pathways.
  • It has been shown to prolong survival in patients with metastatic colorectal cancer.
  • We present a 49-year-old man with metastatic colon cancer who had development of periocular skin toxicity, madarosis, and cicatricial ectropion after the addition of weekly cetuximab infusions to his baseline chemotherapy.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Scars.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237696.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


83. Zenda T, Taniguchi K, Hashimoto T, Takeshita Y, Choto S, Masunaga T, Minato H: Metastatic colon cancer mimicking Crohn's disease. Ann Diagn Pathol; 2007 Dec;11(6):427-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic colon cancer mimicking Crohn's disease.
  • Although upper gastrointestinal endoscopy demonstrated signet-ring cell gastric carcinoma, colonoscopy and barium enema study yielded findings mimicking Crohn's disease in the colon, that is, skipping longitudinal ulcer scarlike strictures, cobblestone appearance, segmental stricture, and pseudosacculations.
  • After total gastrectomy and right-sided hemicolectomy, the final diagnosis of gastric cancer extensively involving the colon, and not of Crohn's disease complicating gastric cancer, was established.
  • Pathologic examination showed that anaplastic cancer with exuberant desmoplastic reaction and infiltration along the mesenteric border principally accounted for the morphological similarities noted between Crohn's disease and metastatic colon cancer in this case.
  • The findings in the present case, together with a review of the literature, suggest that metastatic colon cancer should be considered when Crohn-like colonic findings are encountered, not only in individuals with concurrent cancer in other sites but also in those with distant history of cancer.


84. Gupta N, Miyauchi S, Martindale RG, Herdman AV, Podolsky R, Miyake K, Mager S, Prasad PD, Ganapathy ME, Ganapathy V: Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans. Biochim Biophys Acta; 2005 Jun 30;1741(1-2):215-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans.
  • ATB(0,+) (SLC6A14) is a Na(+)/Cl(-)-coupled arginine transporter expressed at low levels in normal colon.
  • Since arginine and arginine-derived nitric oxide (NO) play a critical role in cancer, we examined the expression of ATB(0,+) in colorectal cancer.
  • Paired normal and cancer tissues from colectomy specimens of 10 patients with colorectal cancer and from the liver tissue of one patient with hepatic metastasis from a colonic primary were used for the analysis of the levels of ATB(0,+) mRNA, inducible NOS (iNOS) mRNA and the corresponding proteins.
  • Tissues samples from the colon, liver, and lymph nodes of an additional patient with metastatic colon cancer were analyzed for ATB(0,+) protein alone.
  • The ATB(0,+) mRNA increased 22.9+/-3.0-fold in colorectal cancer compared to normal tissue and the increase was evident in each of the 10 cases examined. iNOS mRNA increased 5.2+/-1.1-fold in cancer specimens.
  • This study strongly suggests that the upregulation of ATB(0,+) may have a pathogenic role in colorectal cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis / genetics. Nitric Oxide Synthase / analysis. Nitric Oxide Synthase / metabolism. Nitric Oxide Synthase Type II. RNA, Messenger / analysis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905073.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM 65344
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amino Acid Transport Systems, Basic; 0 / RNA, Messenger; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


85. Seleye-Fubara D, Gbobo I: Pathological study of colorectal carcinoma in adult Nigerians: a study of 45 cases. Niger J Med; 2005 Apr-Jun;14(2):167-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The commonest site of this cancer is the rectum and the least occurred in the transverse colon.
  • Most of our patients presented with advanced cancer of stage IV & III of TNM classification (D and C of Astler-Coller System).
  • Patients present when the tumour is in an advanced stage hence poorer prognosis and the ages of the patents is about 10 years earlier than that of Caucasians.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Developing Countries. Female. Hospitals, Teaching. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Nigeria / epidemiology. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083240.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


86. Seemann H, Meran JG: [Meaningfullness and duration of palliative chemotherapy with regard to the quality of life of palliative patients]. Wien Med Wochenschr; 2010 Feb;160(3-4):64-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • I am reporting on a 74-year-old female patient with primary pulmonary and hepatic metastatic colon cancer.
  • As a result of the extended anti-tumour therapy, remissions of the advanced cancer disease could be achieved repeatedly, which lead to a substantial increase of the patient's quality of life.
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Cooperative Behavior. Female. Humans. Interdisciplinary Communication. Neoplasm Staging. Patient Care Team. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Support Oncol. 2008 Jan;6(1):9-13, 15 [18257395.001]
  • [Cites] J BUON. 2007 Oct-Dec;12(4):445-52 [18067201.001]
  • [Cites] Med Oncol. 2009;26(1):32-7 [18498064.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2013-9 [18421054.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Hepatogastroenterology. 2007 Dec;54(80):2232-9 [18265640.001]
  • [Cites] Clin Ther. 2008 Jan;30(1):14-30 [18343240.001]
  • [Cites] Tumori. 2004 Jan-Feb;90(1):73-9 [15143976.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1670-6 [17470860.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5 Suppl 10):S15-8 [17145520.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2006-12 [18421053.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4557-61 [17876013.001]
  • [Cites] BMJ. 1990 Jun 2;300(6737):1458-60 [2379006.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):443-9 [16500914.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Apr;7(4):407-13 [17428161.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343 (13):905-14 [11006366.001]
  • [Cites] J Med. 2004;35(1-6):87-92 [18084867.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Onkologie. 2007 Apr;30(4):169-74 [17396039.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14 ):2311-9 [18390971.001]
  • (PMID = 20300921.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


87. Jaffe T, Schwartz B: Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int J Cancer; 2008 Dec 1;123(11):2543-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways.
  • A direct and novel dose- and time-dependent activation of RhoA, Cdc42 and Rac1 by leptin is demonstrated in these aggressive colon cancer cells.
  • Our findings clearly indicate that leptin activates PI3K and Src kinase pathways in the metastatic colon cancer cells LS174T and HM7.
  • Understanding in-depth the pathways involved in leptin-associated enhanced cell locomotion and invasion may contribute with the design of novel therapeutics to treat obesity-associated advanced colorectal cancer.
  • [MeSH-minor] Cell Line, Tumor. Cell Movement / drug effects. Enzyme Activation / drug effects. Humans. Neoplasm Invasiveness. Phosphatidylinositol 3-Kinases / metabolism. Receptors, Leptin / metabolism. cdc42 GTP-Binding Protein / metabolism. rac1 GTP-Binding Protein / metabolism. rho GTP-Binding Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18767036.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 0 / Receptors, Leptin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 3.6.5.2 / cdc42 GTP-Binding Protein; EC 3.6.5.2 / rac1 GTP-Binding Protein; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


88. Murphy KC: Assessing software impact on clinical workflow and resource utilization. Stud Health Technol Inform; 2009;143:309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The behaviours of two small groups, oncologists and pharmacists, were recorded and analyzed using a case study of patient with metastatic colon cancer.

  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19380953.001).
  • [ISSN] 0926-9630
  • [Journal-full-title] Studies in health technology and informatics
  • [ISO-abbreviation] Stud Health Technol Inform
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


89. DeWitt JM: Endoscopic ultrasound-guided fine-needle aspiration of right adrenal masses: report of 2 cases. J Ultrasound Med; 2008 Feb;27(2):261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first patient had a history of colon cancer and was found to have a right adrenal mass during workup of jaundice.
  • The second patient also had a history of colon cancer and was found to have an enlarging right adrenal mass and a subcarinal mass during follow-up computed tomography.
  • Endoscopic ultrasound-guided FNA showed a pheochromocytoma in the first patient and metastatic colon cancer in the second patient.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18204017.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Foran E, McWilliam P, Kelleher D, Croke DT, Long A: The leukocyte protein L-plastin induces proliferation, invasion and loss of E-cadherin expression in colon cancer cells. Int J Cancer; 2006 Apr 15;118(8):2098-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The leukocyte protein L-plastin induces proliferation, invasion and loss of E-cadherin expression in colon cancer cells.
  • L-plastin, a gene that codes for an actin-bundling protein, is upregulated in the metastatic colon cancer cell line SW620, when compared to its premetastatic counterpart SW480.
  • The aim of our study was to characterise the effect of L-plastin overexpression on SW480 cells in the context of the acquisition of a metastatic phenotype.
  • In addition, the expression of E-cadherin was lost from SW480-LPL cells.
  • Treatment of SW480-LPL cells with cytochalasin B, an inhibitor of endocytosis, attenuated the loss of E-cadherin expression in these cells.
  • The association of L-plastin overexpression with an increased rate of proliferation and invasion, and loss of E-cadherin expression in the SW480 colon cancer cell line indicates that L-plastin plays an important mechanistic role in colorectal cancer metastasis (supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html).
  • [MeSH-major] Blood Proteins / biosynthesis. Cadherins / biosynthesis. Cell Proliferation. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Neoplasm Metastasis
  • [MeSH-minor] Gene Expression Profiling. Humans. Microfilament Proteins. Neoplasm Invasiveness. Phenotype. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16287074.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Cadherins; 0 / LCP1 protein, human; 0 / Microfilament Proteins
  •  go-up   go-down


91. Vickers MM, Easaw JC: Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer. J Gastrointest Cancer; 2008;39(1-4):141-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.
  • BACKGROUND: Capecitabine (XELODA) is a chemotherapeutic agent used widely in the treatment of adjuvant/metastatic colon cancer and metastatic breast cancer.
  • CASE REPORT: Here, we describe three patients treated with adjuvant capecitabine for colon cancer (a 49-year-old East Indian man, a 58-year-old Asian woman, and a 54-year-old Aboriginal man) who developed moderate to severe HFS requiring delay and dose reduction.
  • Hyperpigmentation may also be more common in the non-Caucasian populations but more research is required to determine the ethnic distribution of this finding.

  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Actas Dermosifiliogr. 2007 Sep;98(7):491-3 [17669305.001]
  • [Cites] Breast J. 2003 Jan-Feb;9(1):64-5 [12558679.001]
  • [Cites] Clin Exp Dermatol. 2007 Sep;32(5):519-21 [17509060.001]
  • [Cites] Korean J Intern Med. 2007 Jun;22(2):109-12 [17616027.001]
  • [Cites] Cutis. 2004 Feb;73(2):101-6 [15027515.001]
  • [Cites] J Drugs Dermatol. 2002 Sep;1(2):202-5 [12847748.001]
  • (PMID = 19440857.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


92. Polite BN, Dignam JJ, Olopade OI: Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am; 2005 Jul;89(4):771-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites.
  • Certainly, issues surrounding screening for CRC remain important in understanding the advanced stage of presentation for African Americans.
  • Importantly, even if one were able to eliminate the differences in stage at presentation between African Americans and whites, a survival disadvantage, albeit a much smaller one, would likely persist.
  • This becomes even more important as the life-prolonging options for treating both localized and metastatic colon cancer continue to multiply.
  • Finally, the apparent greater disparity in outcome for African Americans who have stage II disease should be explored in more detail, because this could have an immediate impact on treatment recommendations.
  • For example, a 23-gene signature was recently found to be predictive of recurrence among patients with Dukes B colon cancer [66].


93. Rilling WS, Hohenwalter EJ: Combining local and regional therapeutic modalities to treat hepatic malignancies. Semin Intervent Radiol; 2006 Mar;23(1):33-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatocellular carcinoma and metastatic colon cancer have proven to be challenging problems in oncology today.
  • Local ablation techniques along with intra-arterial therapy may be complementary and therefore increase survival in patients being treated for hepatocellular carcinoma and metastatic colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vasc Interv Radiol. 2002 Dec;13(12):1225-32 [12471186.001]
  • [Cites] J Vasc Interv Radiol. 2005 Jul;16(7):955-61 [16002503.001]
  • [Cites] Ann Oncol. 2001 Dec;12(12):1711-20 [11843249.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1516-24 [11745230.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1409-15 [11677976.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):105-9 [14654911.001]
  • [Cites] AJR Am J Roentgenol. 2003 Oct;181(4):997-1003 [14500217.001]
  • [Cites] J Am Coll Surg. 2003 Nov;197(5):730-8 [14585406.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):299-305 [15273555.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S194-205 [15508085.001]
  • [Cites] Am Surg. 2004 Nov;70(11):947-53 [15586503.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):e92-9 [12902905.001]
  • [Cites] Aliment Pharmacol Ther. 2003 May 15;17(10):1247-61 [12755838.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):500-3 [12749256.001]
  • [Cites] Am J Surg. 2002 Sep;184(3):284-90 [12354601.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jul;179(1):93-101 [12076912.001]
  • [Cites] Liver Transpl Surg. 1999 May;5(3):192-9 [10226109.001]
  • [Cites] Ann Surg Oncol. 2002 Mar;9(2):177-85 [11888876.001]
  • (PMID = 21326718.001).
  • [ISSN] 0739-9529
  • [Journal-full-title] Seminars in interventional radiology
  • [ISO-abbreviation] Semin Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3036303
  • [Keywords] NOTNLM ; Ablation / combined therapy / hepatocellular carcinoma
  •  go-up   go-down


94. Pencreach E, Guérin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP, Guenot D: Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res; 2009 Feb 15;15(4):1297-307
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
  • PURPOSE: Despite recent progress, colon cancer is often resistant to combination chemotherapy, highlighting the need for development of novel therapeutic approaches.
  • We here investigated whether combination of rapamycin and irinotecan was active in human colon cancer models.
  • EXPERIMENTAL DESIGN: Human metastatic tumors were xenografted in nude mice and treated with low doses of irinotecan alone, rapamycin alone, or combination of both drugs.
  • The cellular effects of irinotecan and rapamycin were further characterized for HT-29 and HCT-116 colon cancer cells in vitro.
  • CONCLUSION: These results identify HIF-1alpha as a promising target and provide a rationale for clinical trials of low-dose irinotecan and rapamycin combination toward metastatic colon cancer.

  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190131.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Tumor Suppressor Protein p53; 7673326042 / irinotecan; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; W36ZG6FT64 / Sirolimus; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


95. Uemura S, Maeda H, Munekage M, Yoshioka R, Okabayashi T, Hanazaki K: Hepatic resection for metastatic colon cancer in patients with situs inversus totalis complicated by multiple anomalies of the hepatobiliary system: the first case report. J Gastrointest Surg; 2009 Sep;13(9):1724-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection for metastatic colon cancer in patients with situs inversus totalis complicated by multiple anomalies of the hepatobiliary system: the first case report.
  • CASE: The patient was a 64-year-old man with situs inversus totalis who had previously undergone sigmoidectomy with regional lymphadenectomy for sigmoid colon cancer at age 62.
  • For the treatment of hepatic metastases from sigmoid colon cancer in a patient with situs inversus totalis, "left" hepatic lobectomy, partial hepatectomy, and radiofrequency ablation therapy were performed.
  • [MeSH-minor] Catheter Ablation / methods. Chemotherapy, Adjuvant. Colectomy / methods. Follow-Up Studies. Hepatectomy / methods. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Risk Assessment. Time Factors. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Doppler

  • Genetic Alliance. consumer health - Situs inversus.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Feb 1;51(3):549-52 [6295608.001]
  • [Cites] Arch Surg. 1949 May;58(5):724-30 [18152884.001]
  • [Cites] Jpn J Surg. 1989 Nov;19(6):756-9 [2558246.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):461-3 [16012300.001]
  • [Cites] J Int Coll Surg. 1960 Feb;33:131-48 [13841293.001]
  • [Cites] Transplant Proc. 2007 Jun;39(5):1714-5 [17580229.001]
  • [Cites] Radiographics. 2002 Nov-Dec;22(6):1439-56 [12432114.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1266-8 [14571715.001]
  • [Cites] J Comput Assist Tomogr. 2000 Sep-Oct;24(5):802-8 [11045706.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):1008-10 [9386300.001]
  • [Cites] HPB Surg. 1996;9(3):169-72;discussion 172-3 [8725459.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jan;164(1):103-8 [7998521.001]
  • [Cites] Int Surg. 2006 Jan-Feb;91(1):24-7 [16706098.001]
  • [Cites] J Med Genet. 1996 Jun;33(6):498-503 [8782051.001]
  • [Cites] Surg Gynecol Obstet. 1981 Jan;152(1):43-50 [7455890.001]
  • [Cites] Surg Today. 2003;33(9):702-6 [12928850.001]
  • [Cites] Anat Sci Int. 2002 Jun;77(2):124-7 [12418092.001]
  • [Cites] Am Heart J. 1958 Nov;56(5):761-8 [13582847.001]
  • (PMID = 19415395.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Akman A, Yilmaz E, Mutlu H, Ozdogan M: Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol; 2009 Jul;34(5):e202-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of psoriasis following bevacizumab therapy for colon cancer.
  • We describe a patient with metastatic colon cancer and psoriasis who experienced complete remission of psoriasis during treatment with bevacizumab and combination chemotherapy without any other treatment for psoriasis.

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077094.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


97. Hegde SR, Sun W, Lynch JP: Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol; 2008 Feb;2(1):135-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic and targeted therapy for advanced colon cancer.
  • Colorectal cancer (CRC) is the third most common malignancy and the second most common cause of cancer-related death in the USA.
  • Prognosis is best when the disease is detected early; however, nearly two-thirds of newly diagnosed cases of CRC have lymph node involvement or metastatic disease.
  • For years, 5-fluorouracil (FU)-based regimens represented the only viable treatment option for patients with metastatic CRC.
  • This review aims to discuss current systemic and targeted therapies for metastatic colon cancer with a focus on mechanism of action, indications, toxicity and efficacy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19072376.001).
  • [ISSN] 1747-4132
  • [Journal-full-title] Expert review of gastroenterology & hepatology
  • [ISO-abbreviation] Expert Rev Gastroenterol Hepatol
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK068366; United States / NIDDK NIH HHS / DK / DK068366; United States / NIDDK NIH HHS / DK / T32-DK00706
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents
  • [Number-of-references] 117
  •  go-up   go-down


98. Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK, Schlitt HJ, Berzofsky JA, Strober W: Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res; 2008 May 1;68(9):3467-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we show that in two tumor models (the CT-26 metastatic colon cancer and the 15-12RM fibrosarcoma regressor models), this counter-surveillance mechanism requires the expression of a novel IL-13 receptor, IL-13R alpha(2), on Gr-1(intermediate) cells, because down-regulation of IL-13R alpha(2) expression or the activator protein-1 signal generated by the receptor via in vivo administration of specific small interfering RNA or decoy oligonucleotides leads to loss of TGF-beta(1) production.
  • Taking advantage of this latter fact, we then show in the CT-26 model that counter-immunosurveillance can be inhibited, anti-CT-26-specific CD8(+) cytolytic activity can be restored, and CT-26 metastatic tumor nodules can be greatly decreased by administration of TNF-alpha R-Fc.
  • These studies point to the prevention of metastatic cancer with an available agent with already known clinically acceptable adverse effects and toxicity.
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. Down-Regulation. Drug Delivery Systems. Drug Evaluation, Preclinical. Female. Interleukin-13 / metabolism. Interleukin-13 / pharmacology. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Signal Transduction / drug effects. Survival Analysis. Transforming Growth Factor beta1 / metabolism. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 10;300(2):464-71 [12504107.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Mar;41(3):287-98 [11880205.001]
  • [Cites] J Exp Med. 2003 Mar 17;197(6):687-701 [12642601.001]
  • [Cites] J Allergy Clin Immunol. 2003 Apr;111(4):677-90; quiz 691 [12704343.001]
  • [Cites] Science. 2003 Jun 6;300(5625):1527-8 [12791978.001]
  • [Cites] J Exp Med. 2003 Dec 1;198(11):1741-52 [14657224.001]
  • [Cites] Cancer Immunol Immunother. 2004 Feb;53(2):79-85 [14610620.001]
  • [Cites] Hepatology. 2004 Mar;39(3):676-87 [14999686.001]
  • [Cites] Curr Opin Immunol. 2004 Apr;16(2):157-62 [15023407.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7335-40 [15187109.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):583-94 [15286725.001]
  • [Cites] J Immunol. 1993 Dec 1;151(11):6602-7 [8245488.001]
  • [Cites] J Immunol. 1998 Sep 1;161(5):2317-24 [9725226.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):184-93 [10384115.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):419-24 [15623559.001]
  • [Cites] Ann Rheum Dis. 2005 Nov;64(11):1557-62 [15843448.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):369-80 [16286245.001]
  • [Cites] Nat Med. 2006 Jan;12(1):99-106 [16327802.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):745-50 [16517151.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):7905-12 [17114462.001]
  • [Cites] Neoplasma. 2006;53(6):478-84 [17167715.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1038-45 [17283136.001]
  • [Cites] J Immunol. 2007 May 1;178(9):5859-70 [17442970.001]
  • [Cites] J Rheumatol. 2007 Dec;34(12):2334-42 [17985409.001]
  • [Cites] J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1063-70 [10856136.001]
  • [Cites] Surgery. 2001 Feb;129(2):176-87 [11174711.001]
  • [Cites] Nat Immunol. 2000 Dec;1(6):515-20 [11101874.001]
  • [Cites] Annu Rev Immunol. 2003;21:425-56 [12615888.001]
  • (PMID = 18451175.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AI000432-23
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-13; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / RNA, Small Interfering; 0 / Transforming Growth Factor beta1
  • [Other-IDs] NLM/ NIHMS119905; NLM/ PMC2746996
  •  go-up   go-down


99. Zhang W, Jiang B, Guo Z, Sardet C, Zou B, Lam CS, Li J, He M, Lan HY, Pang R, Hung IF, Tan VP, Wang J, Wong BC: Four-and-a-half LIM protein 2 promotes invasive potential and epithelial-mesenchymal transition in colon cancer. Carcinogenesis; 2010 Jul;31(7):1220-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four-and-a-half LIM protein 2 promotes invasive potential and epithelial-mesenchymal transition in colon cancer.
  • BACKGROUND AND AIMS: Cancer invasion and metastasis may associate with the phenotype transition called epithelial-mesenchymal transition (EMT).
  • We aim to evaluate the impact of four-and-a-half LIM protein 2 (FHL2) on EMT and invasion of colon cancer.
  • Mechanisms of FHL2 on expression or activity of E-cadherin and beta-catenin were assessed.
  • RESULTS: FHL2 was highly expressed in primary and metastatic colon cancer but not in normal tissues.
  • FHL2 was critical for cancer cell adhesion to extracellular matrix, migration and invasion.
  • Moreover, FHL2 acted as a potent EMT inducer by stimulating vimentin and matrix metalloproteinase-9 expressions and causing a loss of E-cadherin, whereas those alterations of EMT markers were not affected by silencing of Smad molecules (typical TGF-beta signal mediators) in FHL2 stable transfectant cells.
  • CONCLUSION: FHL2 is a potent EMT inducer and might be an important mediator for invasion and/or metastasis of colon cancer.
  • [MeSH-minor] Animals. Cadherins / analysis. Cell Adhesion. Cell Movement. HCT116 Cells. Humans. LIM-Homeodomain Proteins. Mice. Neoplasm Invasiveness. Neoplasm Metastasis. beta Catenin / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20460358.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / FHL2 protein, human; 0 / Homeodomain Proteins; 0 / LIM-Homeodomain Proteins; 0 / Muscle Proteins; 0 / Transcription Factors; 0 / beta Catenin
  •  go-up   go-down


100. Culy C: Bevacizumab: antiangiogenic cancer therapy. Drugs Today (Barc); 2005 Jan;41(1):23-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab: antiangiogenic cancer therapy.
  • In addition, bevacizumab has shown antiangiogenic and antitumor activity in several cancer types, recently gaining approval from the FDA for use in combination with fluorouracil-based chemotherapy as a first-line treatment for metastatic cancer of the colon or rectum.
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Clinical Trials as Topic. Colorectal Neoplasms / drug therapy. Humans. Kidney Neoplasms / drug therapy. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Prous Science. All rights reserved.
  • (PMID = 15753967.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  • [Number-of-references] 64
  •  go-up   go-down






Advertisement